BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42:987-1000. [PMID: 16250043 DOI: 10.1002/hep.20920] [Cited by in Crossref: 512] [Cited by in F6Publishing: 432] [Article Influence: 32.0] [Reference Citation Analysis]
Number Citing Articles
1 Vinciguerra M, Foti M. PTEN and SHIP2 phosphoinositide phosphatases as negative regulators of insulin signalling. Arch Physiol Biochem. 2006;112:89-104. [PMID: 16931451 DOI: 10.1080/13813450600711359] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 3.9] [Reference Citation Analysis]
2 Manco M, Bottazzo G, Devito R, Marcellini M, Mingrone G, Nobili V. Nonalcoholic Fatty Liver Disease in Children. Journal of the American College of Nutrition 2008;27:667-76. [DOI: 10.1080/07315724.2008.10719744] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
3 Neyrinck AM, Bindels LB, De Backer F, Pachikian BD, Cani PD, Delzenne NM. Dietary supplementation with chitosan derived from mushrooms changes adipocytokine profile in diet-induced obese mice, a phenomenon linked to its lipid-lowering action. Int Immunopharmacol 2009;9:767-73. [PMID: 19286482 DOI: 10.1016/j.intimp.2009.02.015] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
4 Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem. 2011;22:699-711. [PMID: 21292470 DOI: 10.1016/j.jnutbio.2010.10.002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 11.3] [Reference Citation Analysis]
5 Conde de la Rosa L, Vrenken TE, Buist-Homan M, Faber KN, Moshage H. Metformin protects primary rat hepatocytes against oxidative stress-induced apoptosis. Pharmacol Res Perspect. 2015;3:e00125. [PMID: 26038701 DOI: 10.1002/prp2.125] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
6 Gangopadhyay KK, Singh P. Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. Indian J Endocrinol Metab 2017;21:341-54. [PMID: 28459036 DOI: 10.4103/ijem.IJEM_512_16] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Delgado JS. Evolving trends in nonalcoholic fatty liver disease. Eur J Intern Med. 2008;19:75-82. [PMID: 18249301 DOI: 10.1016/j.ejim.2007.02.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
8 Ricci G, Bersani G, Rossi A, Pigò F, De Fabritiis G, Alvisi V. Bariatric therapy with intragastric balloon improves liver dysfunction and insulin resistance in obese patients. Obes Surg. 2008;18:1438-1442. [PMID: 18369681 DOI: 10.1007/s11695-008-9487-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
9 Harada S, Miyagi K, Obata T, Morimoto Y, Nakamoto K, Kim KI, Kim SK, Kim SR, Tokuyama S. Influence of hyperglycemia on liver inflammatory conditions in the early phase of non-alcoholic fatty liver disease in mice. J Pharm Pharmacol 2017;69:698-705. [PMID: 28220495 DOI: 10.1111/jphp.12705] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
10 Salamone F, Bugianesi E. Nonalcoholic fatty liver disease: the hepatic trigger of the metabolic syndrome. J Hepatol. 2010;53:1146-1147. [PMID: 20817302 DOI: 10.1016/j.jhep.2010.06.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
11 Mak LY, Hui RW, Fung J, Liu F, Wong DK, Cheung KS, Yuen MF, Seto WK. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73:800-806. [PMID: 32504663 DOI: 10.1016/j.jhep.2020.05.040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
12 Leclercq IA, Lebrun VA, Stärkel P, Horsmans YJ. Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. Lab Invest. 2007;87:56-65. [PMID: 17075577 DOI: 10.1038/labinvest.3700489] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 5.1] [Reference Citation Analysis]
13 Shams F, Rafique S, Zahid S, Munir M, Idrees M, Ilyas M, Husnain T. Advances in the role of HCV nonstructural protein 5a (NS5A) of 3a genotype in inducing insulin resistance by possible phosphorylation of AKT/PKB. Sci Rep 2019;9:6150. [PMID: 30992506 DOI: 10.1038/s41598-019-42602-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Francque S, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, Michielsen P, Van Gaal L. Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension. Int J Obes (Lond). 2011;35:270-278. [PMID: 20661251 DOI: 10.1038/ijo.2010.134] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
15 Wang XM, Holz LE, Chowdhury S, Cordoba SP, Evans KA, Gall MG, Vieira de Ribeiro AJ, Zheng YZ, Levy MT, Yu DM, Yao TW, Polak N, Jolly CJ, Bertolino P, McCaughan GW, Gorrell MD. The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury. Immunol Cell Biol 2017;95:443-53. [PMID: 27899813 DOI: 10.1038/icb.2016.116] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
16 Shiffman ML, Gunn NT. Impact of hepatitis C virus therapy on metabolism and public health. Liver Int 2017;37 Suppl 1:13-8. [PMID: 28052632 DOI: 10.1111/liv.13282] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
17 Thyfault JP, Rector RS. Exercise Combats Hepatic Steatosis: Potential Mechanisms and Clinical Implications. Diabetes 2020;69:517-24. [PMID: 32198195 DOI: 10.2337/dbi18-0043] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
18 Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol. 2006;101:2629-2640. [PMID: 16952281 DOI: 10.1111/j.1572-0241.2006.00848.x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 114] [Article Influence: 8.1] [Reference Citation Analysis]
19 Tanaka A, Murohara T, Taguchi I, Eguchi K, Suzuki M, Kitakaze M, Sato Y, Ishizu T, Higashi Y, Yamada H, Nanasato M, Shimabukuro M, Teragawa H, Ueda S, Kodera S, Matsuhisa M, Kadokami T, Kario K, Nishio Y, Inoue T, Maemura K, Oyama J, Ohishi M, Sata M, Tomiyama H, Node K; PROTECT Study Investigators. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. Cardiovasc Diabetol 2016;15:133. [PMID: 27619983 DOI: 10.1186/s12933-016-0449-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
20 Feltenberger JD, Andrade JM, Paraíso A, Barros LO, Filho AB, Sinisterra RD, Sousa FB, Guimarães AL, de Paula AM, Campagnole-Santos MJ, Qureshi M, dos Santos RA, Santos SH. Oral formulation of angiotensin-(1-7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice. Hypertension 2013;62:324-30. [PMID: 23753417 DOI: 10.1161/HYPERTENSIONAHA.111.00919] [Cited by in Crossref: 68] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
21 Xu P, Zhang XG, Li YM, Yu CH, Xu L, Xu GY. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. J Zhejiang Univ Sci B. 2006;7:627-633. [PMID: 16845716 DOI: 10.1631/jzus.2006.b0627] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
22 Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. [PMID: 17081293 DOI: 10.1186/1471-230x-6-33] [Cited by in Crossref: 937] [Cited by in F6Publishing: 391] [Article Influence: 62.5] [Reference Citation Analysis]
23 Lamb P, Harrison S. Metabolic Syndrome and HCV: Where Do We Stand in 2010? Curr Hepatitis Rep 2010;9:133-9. [DOI: 10.1007/s11901-010-0044-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Sun J, Tang Y, Yu X, Xu Y, Liu P, Xiao L, Liu L, Deng Q, Yao P. Flaxseed lignans alleviate high fat diet-induced hepatic steatosis and insulin resistance in mice: Potential involvement of AMP-activated protein kinase. Journal of Functional Foods 2016;24:482-91. [DOI: 10.1016/j.jff.2016.04.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
25 Mitrofanova A, Sosa MA, Fornoni A. Lipid mediators of insulin signaling in diabetic kidney disease. Am J Physiol Renal Physiol. 2019;317:F1241-F1252. [PMID: 31545927 DOI: 10.1152/ajprenal.00379.2019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
26 Dong ZX, Su L, Brymora J, Bird C, Xie Q, George J, Wang JH. Resistin mediates the hepatic stellate cell phenotype. World J Gastroenterol. 2013;19:4475-4485. [PMID: 23901222 DOI: 10.3748/wjg.v19.i28.4475] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
27 He XX, Wu XL, Chen RP, Chen C, Liu XG, Wu BJ, Huang ZM. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016;11:e0162368. [PMID: 27711128 DOI: 10.1371/journal.pone.0162368] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
28 de Castro GS, Calder PC. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. Clinical Nutrition 2018;37:37-55. [DOI: 10.1016/j.clnu.2017.01.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 18.3] [Reference Citation Analysis]
29 Yamabe N, Kang KS, Hur JM, Yokozawa T. Matcha, a powdered green tea, ameliorates the progression of renal and hepatic damage in type 2 diabetic OLETF rats. J Med Food 2009;12:714-21. [PMID: 19735169 DOI: 10.1089/jmf.2008.1282] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
30 Afarideh M, Aryan Z, Ghajar A, Ganji M, Ghaemi F, Saadat M, Heidari B, Mechanick JI, Esteghamati A. Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes. Prim Care Diabetes 2019;13:505-14. [PMID: 31054837 DOI: 10.1016/j.pcd.2019.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 McPherson S, Henderson E, Burt AD, Day CP, Anstee QM. Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2014;60:1055-62. [PMID: 24445215 DOI: 10.1016/j.jhep.2014.01.010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
32 Froylich D, Corcelles R, Daigle C, Boules M, Brethauer S, Schauer P. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg Obes Relat Dis. 2016;12:127-131. [PMID: 26077701 DOI: 10.1016/j.soard.2015.04.004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
33 Linden MA, Meers GM, Ruebel ML, Jenkins NT, Booth FW, Laughlin MH, Ibdah JA, Thyfault JP, Rector RS. Hepatic steatosis development with four weeks of physical inactivity in previously active, hyperphagic OLETF rats. Am J Physiol Regul Integr Comp Physiol 2013;304:R763-71. [PMID: 23467323 DOI: 10.1152/ajpregu.00537.2012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
34 Petersen MC, Shulman GI. Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance. Trends Pharmacol Sci. 2017;38:649-665. [PMID: 28551355 DOI: 10.1016/j.tips.2017.04.004] [Cited by in Crossref: 151] [Cited by in F6Publishing: 135] [Article Influence: 37.8] [Reference Citation Analysis]
35 Cheng B, Gao W, Wu X, Zheng M, Yu Y, Song C, Miao W, Yang Z, He Y, Liu C, Yang W, Yang X, Li Y, Zhang F, Gao Y. Ginsenoside Rg2 Ameliorates High-Fat Diet-Induced Metabolic Disease through SIRT1. J Agric Food Chem 2020;68:4215-26. [PMID: 32181656 DOI: 10.1021/acs.jafc.0c00833] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
36 Buscemi S, Corleo D, Buscemi C, Giordano C. Does iris(in) bring bad news or good news? Eat Weight Disord 2018;23:431-42. [PMID: 28933009 DOI: 10.1007/s40519-017-0431-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
37 Lin YH, Liao YY, Yeh CK, Yang KC, Tsui PH. Ultrasound Entropy Imaging of Nonalcoholic Fatty Liver Disease: Association with Metabolic Syndrome. Entropy (Basel) 2018;20:E893. [PMID: 33266617 DOI: 10.3390/e20120893] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
38 Rachakonda VP, Reeves VL, Aljammal J, Wills RC, Trybula JS, DeLany JP, Kienesberger PC, Kershaw EE. Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity. Obesity (Silver Spring). 2015;23:965-972. [PMID: 25865747 DOI: 10.1002/oby.20960] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
39 Sharma K, Zajc I, Žiberna L. Dietary vitamin D equilibrium in serum ameliorates direct bilirubin associated diabetes mellitus. Chem Biol Interact 2021;337:109399. [PMID: 33503443 DOI: 10.1016/j.cbi.2021.109399] [Reference Citation Analysis]
40 Soresi M, Noto D, Cefalù AB, Martini S, Vigna GB, Fonda M, Manzato E, Cattin L, Fellin R, Averna MR. Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Acta Diabetol. 2013;50:241-249. [PMID: 22684314 DOI: 10.1007/s00592-012-0406-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
41 Mani S, Cao W, Wu L, Wang R. Hydrogen sulfide and the liver. Nitric Oxide 2014;41:62-71. [PMID: 24582857 DOI: 10.1016/j.niox.2014.02.006] [Cited by in Crossref: 95] [Cited by in F6Publishing: 72] [Article Influence: 13.6] [Reference Citation Analysis]
42 Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 2007;275:43-61. [PMID: 17624658 DOI: 10.1016/j.mce.2007.05.015] [Cited by in Crossref: 280] [Cited by in F6Publishing: 227] [Article Influence: 20.0] [Reference Citation Analysis]
43 Sharp KPH, Schultz M, Coppell KJ. Is non-alcoholic fatty liver disease a reflection of what we eat or simply how much we eat? JGH Open 2018;2:59-74. [PMID: 30483565 DOI: 10.1002/jgh3.12040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
44 Pagadala MR, Zein CO, Dasarathy S, Yerian LM, Lopez R, McCullough AJ. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57:528-534. [PMID: 22183820 DOI: 10.1007/s10620-011-2006-2] [Cited by in Crossref: 91] [Cited by in F6Publishing: 76] [Article Influence: 9.1] [Reference Citation Analysis]
45 Andrés-Blasco I, Herrero-Cervera A, Vinué Á, Martínez-Hervás S, Piqueras L, Sanz MJ, Burks DJ, González-Navarro H. Hepatic lipase deficiency produces glucose intolerance, inflammation and hepatic steatosis. J Endocrinol 2015;227:179-91. [PMID: 26423094 DOI: 10.1530/JOE-15-0219] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
46 Rector RS, Thyfault JP. Does physical inactivity cause nonalcoholic fatty liver disease? J Appl Physiol (1985). 2011;111:1828-1835. [PMID: 21565984 DOI: 10.1152/japplphysiol.00384.2011] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
47 Douglas MW, George J. Molecular mechanisms of insulin resistance in chronic hepatitis C. World J Gastroenterol 2009;15:4356-64. [PMID: 19764085 DOI: 10.3748/wjg.15.4356] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
48 Dai Z, Zhou T, Li C, Qi W, Mao Y, Lu J, Yao Y, Li L, Zhang T, Hong H, Li S, Cai W, Yang Z, Ma J, Yang X, Gao G. Intracellular pigment epithelium-derived factor contributes to triglyceride degradation. The International Journal of Biochemistry & Cell Biology 2013;45:2076-86. [DOI: 10.1016/j.biocel.2013.07.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
49 Catta-preta M, Martins MA, Cunha Brunini TM, Mendes-ribeiro AC, Mandarim-de-lacerda CA, Aguila MB. Modulation of cytokines, resistin, and distribution of adipose tissue in C57BL/6 mice by different high-fat diets. Nutrition 2012;28:212-9. [DOI: 10.1016/j.nut.2011.05.011] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
50 Matafome P, Nunes E, Louro T, Amaral C, Crisóstomo J, Rodrigues L, Moedas AR, Monteiro P, Cipriano A, Seiça R. A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia. Naunyn-Schmied Arch Pharmacol 2009;379:241-51. [DOI: 10.1007/s00210-008-0363-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
51 Imajo K, Yoneda M, Ogawa Y, Wada K, Nakajima A. Microbiota and nonalcoholic steatohepatitis. Semin Immunopathol. 2014;36:115-132. [PMID: 24337650 DOI: 10.1007/s00281-013-0404-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
52 de Freitas Júnior JR, Ribeiro IB, de Moura DTH, Sagae VMT, de Souza GMV, de Oliveira GHP, Sánchez-Luna SA, de Souza TF, de Moura ETH, de Oliveira CPMS, Bernardo WM, de Moura EGH. Effects of intragastric balloon placement in metabolic dysfunction-associated fatty liver disease: A systematic review and meta-analysis. World J Hepatol 2021;13:815-29. [PMID: 34367502 DOI: 10.4254/wjh.v13.i7.815] [Reference Citation Analysis]
53 Page J. Nonalcoholic fatty liver disease: the hepatic metabolic syndrome. J Am Acad Nurse Pract. 2012;24:345-351. [PMID: 22672485 DOI: 10.1111/j.1745-7599.2012.00716.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
54 Wei J, Shi M, Wu WQ, Xu H, Wang T, Wang N, Ma JL, Wang YG. IκB kinase-beta inhibitor attenuates hepatic fibrosis in mice. World J Gastroenterol. 2011;17:5203-5213. [PMID: 22215946 DOI: 10.3748/wjg.v17.i47.5203] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
55 Takahashi Y, Inui A, Fujisawa T, Takikawa H, Fukusato T. Histopathological characteristics of non-alcoholic fatty liver disease in children: Comparison with adult cases: Histopathology of NAFLD in children. Hepatology Research 2011;41:1066-74. [DOI: 10.1111/j.1872-034x.2011.00855.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
56 Riley P, Sudarshi D, Johal M, Benedict A, Panteli J, Crook M, O’donohue J. Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study: Weight loss, diet and statins in NAFLD. International Journal of Clinical Practice 2008;62:374-81. [DOI: 10.1111/j.1742-1241.2007.01666.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
57 Mulder P, van den Hoek AM, Kleemann R. The CCR2 Inhibitor Propagermanium Attenuates Diet-Induced Insulin Resistance, Adipose Tissue Inflammation and Non-Alcoholic Steatohepatitis. PLoS One 2017;12:e0169740. [PMID: 28076416 DOI: 10.1371/journal.pone.0169740] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
58 Das SK, Balakrishnan V. Role of cytokines in the pathogenesis of non-alcoholic Fatty liver disease. Indian J Clin Biochem. 2011;26:202-209. [PMID: 22468051 DOI: 10.1007/s12291-011-0121-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 5.2] [Reference Citation Analysis]
59 Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A, Saadoun D, Desbois AC, Sebastiani M, Casato M. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15:1145-1160. [PMID: 27640316 DOI: 10.1016/j.autrev.2016.09.006] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 12.6] [Reference Citation Analysis]
60 Hamaguchi M, Hashimoto Y, Obora A, Kojima T, Fukui M. Non-alcoholic fatty liver disease with obesity as an independent predictor for incident gastric and colorectal cancer: a population-based longitudinal study. BMJ Open Gastroenterol 2019;6:e000295. [PMID: 31275587 DOI: 10.1136/bmjgast-2019-000295] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
61 Francque SM, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, Michielsen P, Van Gaal L. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol. 2012;10:1162-1168; quiz e87. [PMID: 22796457 DOI: 10.1016/j.cgh.2012.06.019] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
62 Fülöp P, Paragh G. Patomechanisms of hepatic steatosis. Orvosi Hetilap 2010;151:323-9. [DOI: 10.1556/oh.2010.28816] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
63 Weickert MO, Loeffelholz CV, Roden M, Chandramouli V, Brehm A, Nowotny P, Osterhoff MA, Isken F, Spranger J, Landau BR, Pfeiffer AFH, Möhlig M. A Thr 94 Ala mutation in human liver fatty acid-binding protein contributes to reduced hepatic glycogenolysis and blunted elevation of plasma glucose levels in lipid-exposed subjects. American Journal of Physiology-Endocrinology and Metabolism 2007;293:E1078-84. [DOI: 10.1152/ajpendo.00337.2007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
64 Park JW, Park WJ, Kuperman Y, Boura-Halfon S, Pewzner-Jung Y, Futerman AH. Ablation of very long acyl chain sphingolipids causes hepatic insulin resistance in mice due to altered detergent-resistant membranes. Hepatology. 2013;57:525-532. [PMID: 22911490 DOI: 10.1002/hep.26015] [Cited by in Crossref: 111] [Cited by in F6Publishing: 102] [Article Influence: 12.3] [Reference Citation Analysis]
65 Masuda K, Ono M, Fukumoto M, Hirose A, Munekage K, Ochi T, Okamoto N, Akagi N, Ogawa Y, Saibara T. Usefulness of Technetium-99 m-2-methoxy-isobutyl-isonitrile liver scintigraphy for evaluating disease activity of non-alcoholic fatty liver disease. Hepatol Res. 2012;42:273-279. [PMID: 22251279 DOI: 10.1111/j.1872-034x.2011.00923.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Tungland B. Short-Chain Fatty Acid Production and Functional Aspects on Host Metabolism. Human Microbiota in Health and Disease. Elsevier; 2018. pp. 37-106. [DOI: 10.1016/b978-0-12-814649-1.00002-8] [Cited by in Crossref: 9] [Article Influence: 3.0] [Reference Citation Analysis]
67 Najjar SM, Russo L. CEACAM1 loss links inflammation to insulin resistance in obesity and non-alcoholic steatohepatitis (NASH). Semin Immunopathol. 2014;36:55-71. [PMID: 24258517 DOI: 10.1007/s00281-013-0407-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
68 He L, Liu X, Wang L, Yang Z. Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials. Medicine (Baltimore) 2016;95:e4947. [PMID: 27759627 DOI: 10.1097/MD.0000000000004947] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
69 Drummen M, Dorenbos E, Vreugdenhil ACE, Raben A, Fogelholm M, Westerterp-plantenga MS, Adam TC. Long-term effects of increased protein intake after weight loss on intrahepatic lipid content and implications for insulin sensitivity: a PREVIEW study. American Journal of Physiology-Endocrinology and Metabolism 2018;315:E885-91. [DOI: 10.1152/ajpendo.00162.2018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
70 He L, He M, Lv X, Pu D, Su P, Liu Z. NF-kappaB binding activity and pro-inflammatory cytokines expression correlate with body mass index but not glycosylated hemoglobin in Chinese population. Diabetes Res Clin Pract 2010;90:73-80. [PMID: 20630610 DOI: 10.1016/j.diabres.2010.06.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
71 Ando H, Oshima Y, Yanagihara H, Hayashi Y, Takamura T, Kaneko S, Fujimura A. Profile of rhythmic gene expression in the livers of obese diabetic KK-Ay mice. Biochemical and Biophysical Research Communications 2006;346:1297-302. [DOI: 10.1016/j.bbrc.2006.06.044] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
72 Matsuzaka T, Kuba M, Koyasu S, Yamamoto Y, Motomura K, Arulmozhiraja S, Ohno H, Sharma R, Shimura T, Okajima Y, Han SI, Aita Y, Mizunoe Y, Osaki Y, Iwasaki H, Yatoh S, Suzuki H, Sone H, Takeuchi Y, Yahagi N, Miyamoto T, Sekiya M, Nakagawa Y, Ema M, Takahashi S, Tokiwa H, Shimano H. Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice. Hepatology 2020;71:1609-25. [PMID: 31529722 DOI: 10.1002/hep.30953] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
73 Nobili V, Manco M, Devito R, Ciampalini P, Piemonte F, Marcellini M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006;24:1553-61. [DOI: 10.1111/j.1365-2036.2006.03161.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 100] [Article Influence: 7.8] [Reference Citation Analysis]
74 Guo Y, Wang S, Wang Y, Zhu T. Silymarin improved diet-induced liver damage and insulin resistance by decreasing inflammation in mice. Pharm Biol 2016;54:2995-3000. [PMID: 27387273 DOI: 10.1080/13880209.2016.1199042] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
75 Kim G, Lee YH, Park YM, Kim J, Kim H, Lee BW, Kang ES, Cha BS, Lee HC, Kim DJ. Use of a Diabetes Self-Assessment Score to Predict Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Medicine (Baltimore) 2015;94:e1103. [PMID: 26166101 DOI: 10.1097/MD.0000000000001103] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
76 Kukla M, Piotrowski D, Waluga M, Hartleb M. Insulin resistance and its consequences in chronic hepatitis C. Clin Exp Hepatol. 2015;1:17-29. [PMID: 28856251 DOI: 10.5114/ceh.2015.51375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
77 Wang J, Tai G. Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development. Target Oncol 2016;11:723-38. [PMID: 27392951 DOI: 10.1007/s11523-016-0446-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
78 Sharp PA. New insights into the role of iron in the development of nonalcoholic fatty liver disease. Hepatology. 2010;52:408-410. [PMID: 20683940 DOI: 10.1002/hep.23774] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
79 Lee WH, Kim SG. AMPK-Dependent Metabolic Regulation by PPAR Agonists. PPAR Res 2010;2010:549101. [PMID: 20814441 DOI: 10.1155/2010/549101] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
80 Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S. ASH and NASH. Dig Dis 2011;29:202-10. [PMID: 21734385 DOI: 10.1159/000323886] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
81 Li X, Heiskanen JS, Ma H, Heianza Y, Guo Y, Kelly TN, He H, Fonseca VA, Chen W, Harville EW, Ruohonen S, Hutri-Kähönen N, Bazzano LA, Raitakari OT, Qi L. Fatty liver index and left ventricular mass: prospective associations from two independent cohorts. J Hypertens 2021;39:961-9. [PMID: 33560053 DOI: 10.1097/HJH.0000000000002716] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Alaei M, Negro F. Hepatitis C virus and glucose and lipid metabolism. Diabetes & Metabolism 2008;34:692-700. [DOI: 10.1016/s1262-3636(08)74606-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
83 Lemoine M, Serfaty L. [Nonalcoholic fatty liver disease]. Presse Med 2012;41:169-89. [PMID: 21723084 DOI: 10.1016/j.lpm.2011.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
84 Guo XF, Li X, Shi M, Li D. n-3 Polyunsaturated Fatty Acids and Metabolic Syndrome Risk: A Meta-Analysis. Nutrients 2017;9:E703. [PMID: 28684692 DOI: 10.3390/nu9070703] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 9.5] [Reference Citation Analysis]
85 Fareed A, Musselman D, Byrd-Sellers J, Vayalapalli S, Casarella J, Drexler K, Phillips L. On-site Basic Health Screening and Brief Health Counseling of Chronic Medical Conditions for Veterans in Methadone Maintenance Treatment. J Addict Med 2010;4:160-6. [PMID: 20823944 DOI: 10.1097/ADM.0b013e3181b6f4e5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
86 Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis. 2007;17:684-698. [PMID: 17560098 DOI: 10.1016/j.numecd.2007.01.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
87 Shin SK, Cho HW, Song SE, Song DK. Catalase and nonalcoholic fatty liver disease. Pflugers Arch 2018;470:1721-37. [PMID: 30120555 DOI: 10.1007/s00424-018-2195-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
88 Tang R, Liu H, Yuan Y, Xie K, Xu P, Liu X, Wen J. Genetic factors associated with risk of metabolic syndrome and hepatocellular carcinoma. Oncotarget 2017;8:35403-11. [PMID: 28515345 DOI: 10.18632/oncotarget.15893] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
89 Hsu CS, Wang PC, Chen JH, Su WC, Tseng TC, Chen HD, Hsiao TH, Wang CC, Lin HH, Shyu RY. Increasing insulin resistance is associated with increased severity and prevalence of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2011;34:994-1004. [PMID: 21848629 DOI: 10.1111/j.1365-2036.2011.04817.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
90 Pérez-Matute P, Pérez-Martínez L, Blanco JR, Oteo JA. Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome. Oxid Med Cell Longev 2013;2013:493413. [PMID: 23970949 DOI: 10.1155/2013/493413] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
91 Caldwell SH, Ikura Y, Iezzoni JC, Liu Z. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)? J Gastroenterol Hepatol. 2007;22 Suppl 1:S11-S19. [PMID: 17567458 DOI: 10.1111/j.1440-1746.2006.04639.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
92 Mohamed J, Nazratun Nafizah AH, Zariyantey AH, Budin SB. Mechanisms of Diabetes-Induced Liver Damage: The role of oxidative stress and inflammation. Sultan Qaboos Univ Med J. 2016;16:e132-e141. [PMID: 27226903 DOI: 10.18295/squmj.2016.16.02.002] [Cited by in Crossref: 118] [Cited by in F6Publishing: 86] [Article Influence: 23.6] [Reference Citation Analysis]
93 Ji BL, Li R, Zhang SH, Gong LL, Wang ZH, Ren W, Li QF. The lipid accumulation product is highly related to serum alanine aminotransferase level in male adults. Nutr Res 2012;32:581-7. [PMID: 22935341 DOI: 10.1016/j.nutres.2012.06.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
94 Uzun H, Oğullar S, Ünal H, Zorba OÜ, Yazar S, Kalkan M. Non-alcoholic fatty liver disease is associated with benign prostate hyperplasia in men and with overactive bladder in women. Scandinavian Journal of Urology 2013;47:497-502. [DOI: 10.3109/21681805.2013.780258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
95 Ibrahim SH, Hirsova P, Malhi H, Gores GJ. Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Dig Dis Sci 2016;61:1325-36. [PMID: 26626909 DOI: 10.1007/s10620-015-3977-1] [Cited by in Crossref: 111] [Cited by in F6Publishing: 99] [Article Influence: 18.5] [Reference Citation Analysis]
96 Soverini V, Persico M, Bugianesi E, Forlani G, Salamone F, Massarone M, La Mura V, Mazzotti A, Bruno A, Marchesini G. HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. Acta Diabetol. 2011;48:337-343. [PMID: 21574001 DOI: 10.1007/s00592-011-0293-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
97 Lemoine M, Ingiliz P. Liver injury in HIV monoinfected patients: should we turn a blind eye to it? Clin Res Hepatol Gastroenterol 2012;36:441-7. [PMID: 23079114 DOI: 10.1016/j.clinre.2012.06.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
98 Barreyro FJ, Kobayashi S, Bronk SF, Werneburg NW, Malhi H, Gores GJ. Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem 2007;282:27141-54. [PMID: 17626006 DOI: 10.1074/jbc.M704391200] [Cited by in Crossref: 144] [Cited by in F6Publishing: 84] [Article Influence: 10.3] [Reference Citation Analysis]
99 Hao YR, Tang FJ, Zhang X, Wang H. Suppression of NF-κB activation by PDLIM2 restrains hepatic lipogenesis and inflammation in high fat diet induced mice. Biochem Biophys Res Commun 2018;503:564-71. [PMID: 29852170 DOI: 10.1016/j.bbrc.2018.05.187] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
100 Takahashi Y, Fukusato T. Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology. World J Gastroenterol. 2010;16:5280-5285. [PMID: 21072890 DOI: 10.3748/wjg.v16.i42.5280] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
101 Mabuza LP, Gamede MW, Maikoo S, Booysen IN, Nguban PS, Khathi A. Hepatoprotective Effects of a Ruthenium(II) Schiff Base Complex in Rats with Diet-Induced Prediabetes. Curr Ther Res Clin Exp 2019;91:66-72. [PMID: 31871510 DOI: 10.1016/j.curtheres.2019.100570] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 de Paula Simino LA, de Fante T, Figueiredo Fontana M, Oliveira Borges F, Torsoni MA, Milanski M, Velloso LA, Souza Torsoni A. Lipid overload during gestation and lactation can independently alter lipid homeostasis in offspring and promote metabolic impairment after new challenge to high-fat diet. Nutr Metab (Lond) 2017;14:16. [PMID: 28239403 DOI: 10.1186/s12986-017-0168-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
103 van den Berg EH, Gruppen EG, Ebtehaj S, Bakker SJL, Tietge UJF, Dullaart RPF. Cholesterol efflux capacity is impaired in subjects with an elevated Fatty Liver Index, a proxy of non-alcoholic fatty liver disease. Atherosclerosis 2018;277:21-7. [PMID: 30170220 DOI: 10.1016/j.atherosclerosis.2018.07.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
104 Youn Y, Kim YS. Inhibitory effects of Citrus unshiu pericarpium extracts on palmitate-induced lipotoxicity in HepG2 cells. Food Sci Biotechnol 2016;25:1709-17. [PMID: 30263466 DOI: 10.1007/s10068-016-0262-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
105 Suriguga S, Luangmonkong T, Mutsaers HAM, Groothuis GMM, Olinga P. Host microbiota dictates the proinflammatory impact of LPS in the murine liver. Toxicol In Vitro 2020;67:104920. [PMID: 32590029 DOI: 10.1016/j.tiv.2020.104920] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
106 Wang CC, Hsu CS, Liu CJ, Kao JH, Chen DS. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol. 2008;23:779-782. [PMID: 18028349 DOI: 10.1111/j.1440-1746.2007.05216.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 4.6] [Reference Citation Analysis]
107 Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, Akarca U. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease: . European Journal of Gastroenterology & Hepatology 2010;22:18-23. [DOI: 10.1097/meg.0b013e32832e2baf] [Cited by in Crossref: 75] [Cited by in F6Publishing: 43] [Article Influence: 6.8] [Reference Citation Analysis]
108 Kadayifci A, Merriman RB, Bass NM. Medical Treatment of Non-alcoholic Steatohepatitis. Clinics in Liver Disease 2007;11:119-40. [DOI: 10.1016/j.cld.2007.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
109 Yang J, Fernández-Galilea M, Martínez-Fernández L, González-Muniesa P, Pérez-Chávez A, Martínez JA, Moreno-Aliaga MJ. Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation. Nutrients 2019;11:E872. [PMID: 31003450 DOI: 10.3390/nu11040872] [Cited by in Crossref: 60] [Cited by in F6Publishing: 44] [Article Influence: 30.0] [Reference Citation Analysis]
110 Wang X, Nath A, Yang X, Portis A, Walton SP, Chan C. Synergy analysis reveals association between insulin signaling and desmoplakin expression in palmitate treated HepG2 cells. PLoS One 2011;6:e28138. [PMID: 22132232 DOI: 10.1371/journal.pone.0028138] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
111 Bugianesi E, Gastaldelli A. Hepatic and cardiac steatosis: are they coupled? Heart Fail Clin. 2012;8:663-670. [PMID: 22999247 DOI: 10.1016/j.hfc.2012.06.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
112 Marques LS, Zborowski VA, Heck SO, Fulco BCW, Nogueira CW. 4,4'-Dichloro-diphenyl diselenide modulated oxidative stress that differently affected peripheral tissues in streptozotocin-exposed mice. Can J Physiol Pharmacol 2021;99:943-51. [PMID: 33861646 DOI: 10.1139/cjpp-2020-0652] [Reference Citation Analysis]
113 Bozzetto L, Prinster A, Mancini M, Giacco R, De Natale C, Salvatore M, Riccardi G, Rivellese AA, Annuzzi G. Liver fat in obesity: role of type 2 diabetes mellitus and adipose tissue distribution. Eur J Clin Invest 2011;41:39-44. [PMID: 20825466 DOI: 10.1111/j.1365-2362.2010.02372.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
114 Li X, Pang X, Zhang Q, Qu Q, Hou Z, Liu Z, Lv L, Na G, Zhang W, Sun C, Li Y. Long-Term Single and Joint Effects of Excessive Daytime Napping on the HOMA-IR Index and Glycosylated Hemoglobin: A Prospective Cohort Study. Medicine (Baltimore) 2016;95:e2734. [PMID: 26844520 DOI: 10.1097/MD.0000000000002734] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
115 Russo GI, Cimino S, Fragalà E, Privitera S, La Vignera S, Condorelli R, Calogero AE, Chisari M, Castelli T, Favilla V, Morgia G. Relationship between non-alcoholic fatty liver disease and benign prostatic hyperplasia/lower urinary tract symptoms: new insights from an Italian cross-sectional study. World J Urol 2015;33:743-51. [PMID: 25189458 DOI: 10.1007/s00345-014-1392-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
116 Neves C, Rodrigues T, Sereno J, Simões C, Castelhano J, Gonçalves J, Bento G, Gonçalves S, Seiça R, Domingues MR, Castelo-Branco M, Matafome P. Dietary Glycotoxins Impair Hepatic Lipidemic Profile in Diet-Induced Obese Rats Causing Hepatic Oxidative Stress and Insulin Resistance. Oxid Med Cell Longev 2019;2019:6362910. [PMID: 31341532 DOI: 10.1155/2019/6362910] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
117 Bedi O, Aggarwal S, Trehanpati N, Ramakrishna G, Krishan P. Molecular and Pathological Events Involved in the Pathogenesis of Diabetes-Associated Nonalcoholic Fatty Liver Disease. J Clin Exp Hepatol 2019;9:607-18. [PMID: 31695251 DOI: 10.1016/j.jceh.2018.10.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
118 Harris K, Smith L. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. Ann Pharmacother. 2013;47:1348-1352. [PMID: 24259699 DOI: 10.1177/1060028013503108] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
119 Alkhouri N, Lopez R, Berk M, Feldstein AE. Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol 2009;43:985-9. [PMID: 19525859 DOI: 10.1097/MCG.0b013e3181a0998d] [Cited by in Crossref: 55] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
120 Sheng X, Wang M, Lu M, Xi B, Sheng H, Zang YQ. Rhein ameliorates fatty liver disease through negative energy balance, hepatic lipogenic regulation, and immunomodulation in diet-induced obese mice. American Journal of Physiology-Endocrinology and Metabolism 2011;300:E886-93. [DOI: 10.1152/ajpendo.00332.2010] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
121 Lee D, Kim YM, Jung K, Chin YW, Kang KS. Alpha-Mangostin Improves Insulin Secretion and Protects INS-1 Cells from Streptozotocin-Induced Damage. Int J Mol Sci 2018;19:E1484. [PMID: 29772703 DOI: 10.3390/ijms19051484] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
122 Qureshi K, Abrams GA. Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome. Clin Obes 2016;6:117-23. [PMID: 26856683 DOI: 10.1111/cob.12132] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
123 Valverde AM, González-Rodríguez A. IRS2 and PTP1B: Two opposite modulators of hepatic insulin signalling. Arch Physiol Biochem 2011;117:105-15. [PMID: 21401320 DOI: 10.3109/13813455.2011.557386] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
124 Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A, Fabiani S, Marchi S, Ferri C, Ferrannini E, Fallahi P. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes. 2014;5:586-600. [PMID: 25317237 DOI: 10.4239/wjd.v5.i5.586] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 45] [Article Influence: 7.4] [Reference Citation Analysis]
125 van den Berg EH, Gruppen EG, James RW, Bakker SJL, Dullaart RPF. Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol. J Lipid Res 2019;60:168-75. [PMID: 30455362 DOI: 10.1194/jlr.P088997] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
126 Torres DM, Harrison SA. Hepatitis C, insulin resistance, and steatosis. Curr hepatitis rep 2007;6:129-37. [DOI: 10.1007/s11901-007-0015-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
127 Sommerfeld A, Krones-Herzig A, Herzig S. Transcriptional co-factors and hepatic energy metabolism. Mol Cell Endocrinol 2011;332:21-31. [PMID: 21112373 DOI: 10.1016/j.mce.2010.11.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
128 Lee YB, Kim YS, Lee DH, Kim HY, Lee JI, Ahn HS, Sohn TS, Lee TK, Song JY, Yeo CD, Hong M, Han K, Jeong SC, Chae HS. Association between HOMA-IR and Lung Function in Korean Young Adults based on the Korea National Health and Nutrition Examination Survey. Sci Rep 2017;7:11726. [PMID: 28916790 DOI: 10.1038/s41598-017-11337-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
129 Yang MH, Sung J, Gwak G. The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. Journal of Clinical Lipidology 2016;10:289-98. [DOI: 10.1016/j.jacl.2015.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
130 Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. Journal of Endocrinology 2013;218:R25-36. [DOI: 10.1530/joe-13-0201] [Cited by in Crossref: 155] [Cited by in F6Publishing: 72] [Article Influence: 19.4] [Reference Citation Analysis]
131 Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol. 2017;23:6571-6592. [PMID: 29085206 DOI: 10.3748/wjg.v23.i36.6571] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 63] [Article Influence: 26.0] [Reference Citation Analysis]
132 Watanabe K, Ohnishi S, Manabe I, Nagai R, Kadowaki T. KLF6 in nonalcoholic fatty liver disease: role of fibrogenesis and carcinogenesis. Gastroenterology 2008;135:309-12. [PMID: 18558090 DOI: 10.1053/j.gastro.2008.06.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
133 Guo XF, Yang B, Tang J, Li D. Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials. Clin Nutr 2018;37:113-22. [PMID: 28161092 DOI: 10.1016/j.clnu.2017.01.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
134 Zhu MJ, Sun LJ, Liu YQ, Feng YL, Tong HT, Hu YH, Zhao Z. Blood F2-isoprostanes are significantly associated with abnormalities of lipid status in rats with steatosis. World J Gastroenterol 2008;14:4677-83. [PMID: 18698683 DOI: 10.3748/wjg.14.4677] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
135 Qiu S, Cai X, Sun Z, Li L, Zügel M, Steinacker JM, Schumann U. Association between physical activity and risk of nonalcoholic fatty liver disease: a meta-analysis. Therap Adv Gastroenterol 2017;10:701-13. [PMID: 28932271 DOI: 10.1177/1756283X17725977] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
136 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
137 Girard J, Lafontan M. Impact of visceral adipose tissue on liver metabolism and insulin resistance. Part II: Visceral adipose tissue production and liver metabolism. Diabetes Metab 2008;34:439-45. [PMID: 18562233 DOI: 10.1016/j.diabet.2008.04.002] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
138 Cua IH, Hui JM, Bandara P, Kench JG, Farrell GC, McCaughan GW, George J. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007;46:66-73. [PMID: 17596870 DOI: 10.1002/hep.21703] [Cited by in Crossref: 95] [Cited by in F6Publishing: 94] [Article Influence: 6.8] [Reference Citation Analysis]
139 Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Med J 2017;135:277-95. [DOI: 10.1590/1516-3180.2016.0306311216] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
140 Rodrigues MH, Bruno AS, Nahas-Neto J, Sandrim VC, Muniz LG, Nahas EA. Evaluation of clinical and inflammatory markers of nonalcoholic fatty liver disease in postmenopausal women with metabolic syndrome. Metab Syndr Relat Disord 2014;12:330-8. [PMID: 25051240 DOI: 10.1089/met.2013.0140] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
141 Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol. 2007;47:142-156. [PMID: 17512085 DOI: 10.1016/j.jhep.2007.04.002] [Cited by in Crossref: 210] [Cited by in F6Publishing: 191] [Article Influence: 15.0] [Reference Citation Analysis]
142 Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2014;20:569-577. [PMID: 24574727 DOI: 10.3748/wjg.v20.i2.569] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
143 Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol. 2009;15:1537-1547. [PMID: 19340895 DOI: 10.3748/wjg.15.1537] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 80] [Article Influence: 7.1] [Reference Citation Analysis]
144 Lim DW, Kim H, Kim YM, Chin YW, Park WH, Kim JE. Drug repurposing in alternative medicine: herbal digestive Sochehwan exerts multifaceted effects against metabolic syndrome. Sci Rep 2019;9:9055. [PMID: 31227732 DOI: 10.1038/s41598-019-45099-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
145 Nah EH, Park JY. Metabolic Characteristics and Associated Factors of Nonalcoholic Fatty Liver Disease Diagnosed at Medical Checkups. Ann Lab Med 2008;28:244-50. [DOI: 10.3343/kjlm.2008.28.3.244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
146 Ohgo H, Yokoyama H, Hirose H, Kawabe H, Saito I, Tomita K, Hibi T. Significance of ALT/AST ratio for specifying subjects with metabolic syndrome in its silent stage. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2009;3:3-6. [DOI: 10.1016/j.dsx.2008.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
147 Chen ZW, Chen LY, Dai HL, Chen JH, Fang LZ. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B. 2008;9:616-622. [PMID: 18763311 DOI: 10.1631/jzus.b0720016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
148 Engelmann G, Hoffmann GF, Grulich-Henn J, Teufel U. Alanine aminotransferase elevation in obese infants and children: a marker of early onset non alcoholic Fatty liver disease. Hepat Mon 2014;14:e14112. [PMID: 24748893 DOI: 10.5812/hepatmon.14112] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
149 Stimac D, Majanović SK, Turk T, Kezele B, Licul V, Orlić ZC. Intragastric balloon treatment for obesity: results of a large single center prospective study. Obes Surg 2011;21:551-5. [PMID: 21170685 DOI: 10.1007/s11695-010-0310-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
150 Julian CG, Yang IV, Browne VA, Vargas E, Rodriguez C, Pedersen BS, Moore LG, Schwartz DA. Inhibition of peroxisome proliferator-activated receptor γ: a potential link between chronic maternal hypoxia and impaired fetal growth. FASEB J 2014;28:1268-79. [PMID: 24307415 DOI: 10.1096/fj.13-239749] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
151 Lee MY, Choi R, Kim HM, Cho EJ, Kim BH, Choi YS, Naowaboot J, Lee EY, Yang YC, Shin JY, Shin YG, Chung CH. Peroxisome proliferator-activated receptor δ agonist attenuates hepatic steatosis by anti-inflammatory mechanism. Exp Mol Med 2012;44:578-85. [PMID: 22824914 DOI: 10.3858/emm.2012.44.10.066] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
152 Pagadala M, Zein CO, Mccullough AJ. Predictors of Steatohepatitis and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease. Clinics in Liver Disease 2009;13:591-606. [DOI: 10.1016/j.cld.2009.07.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
153 Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care. 2006;9:637-642. [PMID: 16912563 DOI: 10.1097/01.mco.0000241677.40170.17] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 5.1] [Reference Citation Analysis]
154 Xie Y, Zhang Y, Guo Z, Zeng H, Zheng B. Effect of Alkaloids from Nelumbinis Plumula against Insulin Resistance of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Mice. J Diabetes Res 2016;2016:3965864. [PMID: 27761469 DOI: 10.1155/2016/3965864] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
155 Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl). 2009;87:679-695. [PMID: 19352614 DOI: 10.1007/s00109-009-0464-1] [Cited by in Crossref: 188] [Cited by in F6Publishing: 159] [Article Influence: 15.7] [Reference Citation Analysis]
156 Lehtonen H, Suomela J, Tahvonen R, Vaarno J, Venojärvi M, Viikari J, Kallio H. Berry meals and risk factors associated with metabolic syndrome. Eur J Clin Nutr 2010;64:614-21. [DOI: 10.1038/ejcn.2010.27] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
157 Brunt EM. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Seminars in Diagnostic Pathology 2005;22:330-8. [DOI: 10.1053/j.semdp.2006.04.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 3.6] [Reference Citation Analysis]
158 Mak LY, Lee CH, Cheung KS, Wong DK, Liu F, Hui RW, Fung J, Xu A, Lam KS, Yuen MF, Seto WK. Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. Liver Int 2019;39:1217-25. [PMID: 30912255 DOI: 10.1111/liv.14104] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
159 De Gottardi A, Vinciguerra M, Sgroi A, Moukil M, Ravier-dall'antonia F, Pazienza V, Pugnale P, Foti M, Hadengue A. Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes. Lab Invest 2007;87:792-806. [DOI: 10.1038/labinvest.3700590] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
160 Fakhoury-sayegh N, Trak-smayra V, Sayegh R, Haidar F, Obeid O, Asmar S, Khazzaka A. Fructose threshold for inducing organ damage in a rat model of nonalcoholic fatty liver disease. Nutrition Research 2019;62:101-12. [DOI: 10.1016/j.nutres.2018.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
161 Matafome P, Seiça R. Function and Dysfunction of Adipose Tissue. Adv Neurobiol 2017;19:3-31. [PMID: 28933059 DOI: 10.1007/978-3-319-63260-5_1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
162 Moucari R, Marcellin P, Asselah T. Stéatose au cours de l’hépatite chronique C : rôle de l’insulino-résistance et des facteurs viraux. Gastroentérologie Clinique et Biologique 2007;31:643-54. [DOI: 10.1016/s0399-8320(07)91911-9] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
163 Zhou D, Pan YX. Pathophysiological basis for compromised health beyond generations: role of maternal high-fat diet and low-grade chronic inflammation. J Nutr Biochem 2015;26:1-8. [PMID: 25440222 DOI: 10.1016/j.jnutbio.2014.06.011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
164 Schwarz JM, Clearfield M, Mulligan K. Conversion of Sugar to Fat: Is Hepatic de Novo Lipogenesis Leading to Metabolic Syndrome and Associated Chronic Diseases? J Am Osteopath Assoc 2017;117:520-7. [PMID: 28759094 DOI: 10.7556/jaoa.2017.102] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
165 Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007;133:496-506. [PMID: 17681171 DOI: 10.1053/j.gastro.2007.04.068] [Cited by in Crossref: 350] [Cited by in F6Publishing: 317] [Article Influence: 25.0] [Reference Citation Analysis]
166 Pirimoglu B, Sade R, Islek A, Kantarci M. The Liver Fat Fraction and Abdominal Subcutaneous and Visceral Fat Volume Distribution in Normal-Weight, Overweight, and Obese Children Using a New Magnetic Resonance Imaging Technique. J Comput Assist Tomogr 2019;43:194-9. [PMID: 30371614 DOI: 10.1097/RCT.0000000000000803] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 He X, Gao J, Hou H, Qi Z, Chen H, Zhang X. Inhibition of Mitochondrial Fatty Acid Oxidation Contributes to Development of Nonalcoholic Fatty Liver Disease Induced by Environmental Cadmium Exposure. Environ Sci Technol 2019;53:13992-4000. [DOI: 10.1021/acs.est.9b05131] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
168 Davoodi I, Rahimi R, Abdollahi M, Farzaei F, Farzaei MH, Memariani Z, Najafi F. Promising effect of Rosa damascena extract on high-fat diet-induced nonalcoholic fatty liver. J Tradit Complement Med 2017;7:508-14. [PMID: 29034200 DOI: 10.1016/j.jtcme.2017.01.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
169 Riley P, O'Donohue J, Crook M. A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease. J Clin Pathol 2007;60:1384-91. [PMID: 17483247 DOI: 10.1136/jcp.2006.044891] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
170 Desouza CV, Shivaswamy V. Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review. Clin Med Insights Endocrinol Diabetes 2010;3:43-51. [PMID: 22879786 DOI: 10.4137/cmed.s5372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
171 Lonardo A, Caldwell SH, Loria P. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Review of Endocrinology & Metabolism 2014;5:403-23. [DOI: 10.1586/eem.10.5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
172 Abeysekera KWM, Fernandes GS, Hammerton G, Portal AJ, Gordon FH, Heron J, Hickman M. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study. Lancet Gastroenterol Hepatol 2020;5:295-305. [PMID: 31954687 DOI: 10.1016/S2468-1253(19)30419-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 30.0] [Reference Citation Analysis]
173 Stanimirovic J, Obradovic M, Jovanovic A, Sudar-milovanovic E, Zafirovic S, Pitt SJ, Stewart AJ, Isenovic ER. A high fat diet induces sex-specific differences in hepatic lipid metabolism and nitrite/nitrate in rats. Nitric Oxide 2016;54:51-9. [DOI: 10.1016/j.niox.2016.02.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
174 Lambert JE, Parnell JA, Eksteen B, Raman M, Bomhof MR, Rioux KP, Madsen KL, Reimer RA. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol 2015;15:169. [PMID: 26635079 DOI: 10.1186/s12876-015-0400-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
175 Safi SZ, Shah H, Siok Yan GO, Qvist R. Insulin resistance provides the connection between hepatitis C virus and diabetes. Hepat Mon 2015;15:e23941. [PMID: 25741369 DOI: 10.5812/hepatmon.23941] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
176 Mourad AA, Heeba GH, Taye A, El-moselhy MA. Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats. Fundam Clin Pharmacol 2013;27:489-97. [DOI: 10.1111/j.1472-8206.2012.01048.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
177 Diehl T, Mullins R, Kapogiannis D. Insulin resistance in Alzheimer's disease. Transl Res 2017;183:26-40. [PMID: 28034760 DOI: 10.1016/j.trsl.2016.12.005] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 11.2] [Reference Citation Analysis]
178 Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology. 2006;44:1648-1655. [PMID: 17133473 DOI: 10.1002/hep.21429] [Cited by in Crossref: 100] [Cited by in F6Publishing: 99] [Article Influence: 7.1] [Reference Citation Analysis]
179 Radwan HA, Hamed EH, Saleh OM. Significance of Serum Adiponectin and Insulin Resistance Levels in Diagnosis of Egyptian Patients with Chronic Liver Disease and HCC. Asian Pac J Cancer Prev 2019;20:1833-9. [PMID: 31244307 DOI: 10.31557/APJCP.2019.20.6.1833] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
180 Nassir F, Ibdah JA. Sirtuins and nonalcoholic fatty liver disease. World J Gastroenterol. 2016;22:10084-10092. [PMID: 28028356 DOI: 10.3748/wjg.v22.i46.10084] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 47] [Article Influence: 13.5] [Reference Citation Analysis]
181 Stiuso P, Scognamiglio I, Murolo M, Ferranti P, De Simone C, Rizzo MR, Tuccillo C, Caraglia M, Loguercio C, Federico A. Serum oxidative stress markers and lipidomic profile to detect NASH patients responsive to an antioxidant treatment: a pilot study. Oxid Med Cell Longev 2014;2014:169216. [PMID: 24987492 DOI: 10.1155/2014/169216] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
182 Nam HH, Jun DW, Jeon HJ, Lee JS, Saeed WK, Kim EK. Osthol attenuates hepatic steatosis via decreased triglyceride synthesis not by insulin resistance. World J Gastroenterol. 2014;20:11753-11761. [PMID: 25206279 DOI: 10.3748/wjg.v20.i33.11753] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
183 Benini F, Pigozzi MG, Baisini O, Romanini L, Ahmed H, Pozzi A, Ricci C, Lanzini A. Increased serum gamma-glutamyl-transpeptidase concentration is associated with nonalcoholic steatosis and not with cholestasis in patients with chronic hepatitis C. J Gastroenterol Hepatol 2007;22:1621-6. [DOI: 10.1111/j.1440-1746.2006.04733.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
184 Lemieux GA, Ashrafi K. Insights and challenges in using C. elegans for investigation of fat metabolism. Crit Rev Biochem Mol Biol 2015;50:69-84. [PMID: 25228063 DOI: 10.3109/10409238.2014.959890] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
185 Li H, Wang L, Yan X, Liu Q, Yu C, Wei H, Li Y, Zhang X, He F, Jiang Y. A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease. J Proteome Res 2011;10:2797-806. [PMID: 21563774 DOI: 10.1021/pr200047c] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
186 Toblli JE, Muñoz MC, Cao G, Mella J, Pereyra L, Mastai R. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring) 2008;16:770-6. [PMID: 18239590 DOI: 10.1038/oby.2007.114] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]
187 Pinzani M. Pathophysiology of non-alcoholic steatohepatitis and basis for treatment. Dig Dis 2011;29:243-8. [PMID: 21734391 DOI: 10.1159/000323928] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
188 Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009;115:5651-5661. [PMID: 19834957 DOI: 10.1002/cncr.24687] [Cited by in Crossref: 257] [Cited by in F6Publishing: 229] [Article Influence: 23.4] [Reference Citation Analysis]
189 Chen L, Lin X, Teng H. Emulsions loaded with dihydromyricetin enhance its transport through Caco-2 monolayer and improve anti-diabetic effect in insulin resistant HepG2 cell. Journal of Functional Foods 2020;64:103672. [DOI: 10.1016/j.jff.2019.103672] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 16.0] [Reference Citation Analysis]
190 Rajesh Y, Sarkar D. Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1290. [PMID: 32443737 DOI: 10.3390/cancers12051290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
191 Wang YY, Lin SY, Chuang YH, Sheu WH, Tung KC, Chen CJ. Activation of hepatic inflammatory pathways by catecholamines is associated with hepatic insulin resistance in male ischemic stroke rats. Endocrinology 2014;155:1235-46. [PMID: 24437486 DOI: 10.1210/en.2013-1593] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
192 Yu Q, Jiang Z, Zhang L. Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease. Pharmacol Ther 2018;190:81-90. [PMID: 29684468 DOI: 10.1016/j.pharmthera.2018.04.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
193 El-ashmawy HM, Ahmed AM. Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. European Journal of Gastroenterology & Hepatology 2019;31:859-64. [DOI: 10.1097/meg.0000000000001354] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
194 Buqué X, Martínez MJ, Cano A, Miquilena-Colina ME, García-Monzón C, Aspichueta P, Ochoa B. A subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker rats. J Lipid Res 2010;51:500-13. [PMID: 19783528 DOI: 10.1194/jlr.M001966] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
195 Schreuder TC, Verwer BJ, van Nieuwkerk CM, Mulder CJ. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol. 2008;14:2474-2486. [PMID: 18442193 DOI: 10.3748/wjg.14.2474] [Cited by in CrossRef: 111] [Cited by in F6Publishing: 103] [Article Influence: 9.3] [Reference Citation Analysis]
196 Howell J, Yiu M, Gibson R, Thomson B, Stella D, Gorelik A, Prichard PJ, Nicoll AJ. Type 2 diabetes does not worsen prognosis in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2011;35:214-220. [PMID: 21501980 DOI: 10.1016/j.clinre.2010.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
197 Ryll A, Bucher J, Bonin A, Bongard S, Gonçalves E, Saez-Rodriguez J, Niklas J, Klamt S. A model integration approach linking signalling and gene-regulatory logic with kinetic metabolic models. Biosystems 2014;124:26-38. [PMID: 25063553 DOI: 10.1016/j.biosystems.2014.07.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
198 Auguet T, Terra X, Porras JA, Orellana-Gavaldà JM, Martinez S, Aguilar C, Lucas A, Pellitero S, Hernández M, Del Castillo D. Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease. Clin Biochem. 2013;46:202-208. [PMID: 23174488 DOI: 10.1016/j.clinbiochem.2012.11.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
199 Tsochatzis EA, Manolakopoulos S, Papatheodoridis GV, Archimandritis AJ. Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. Scand J Gastroenterol. 2009;44:6-14. [PMID: 18661429 DOI: 10.1080/00365520802273058] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
200 Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, Papa G, Rabuazzo AM, Purrello F. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis. 2008;40:194-199. [PMID: 18054848 DOI: 10.1016/j.dld.2007.10.003] [Cited by in Crossref: 191] [Cited by in F6Publishing: 178] [Article Influence: 13.6] [Reference Citation Analysis]
201 Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol. 2008;14:185-192. [PMID: 18186553 DOI: 10.3748/wjg.14.185] [Cited by in CrossRef: 197] [Cited by in F6Publishing: 183] [Article Influence: 15.2] [Reference Citation Analysis]
202 Sowers JR. The Cardiometabolic Syndrome and Liver Disease. J CardioMetab Syndrome 2008;3:5-6. [DOI: 10.1111/j.1559-4572.2008.08248.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
203 Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int. 2006;26:1175-1186. [PMID: 17105582 DOI: 10.1111/j.1478-3231.2006.01342.x] [Cited by in Crossref: 519] [Cited by in F6Publishing: 432] [Article Influence: 37.1] [Reference Citation Analysis]
204 Iyer S, Upadhyay PK, Majumdar SS, Nagarajan P. Animal Models Correlating Immune Cells for the Development of NAFLD/NASH. J Clin Exp Hepatol 2015;5:239-45. [PMID: 26628841 DOI: 10.1016/j.jceh.2015.06.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
205 Wattacheril J. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:141-9. [PMID: 32033760 DOI: 10.1016/j.gtc.2019.10.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
206 Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, Hartmann-Heurtier A, Bruckert E, Poynard T;  LIDO Study Group. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology. 2010;51:445-453. [PMID: 19877169 DOI: 10.1002/hep.23270] [Cited by in Crossref: 238] [Cited by in F6Publishing: 224] [Article Influence: 21.6] [Reference Citation Analysis]
207 Hellerbrand C. Pathophysiological similarities and synergisms in alcoholic and non-alcoholic steatohepatitis. Dig Dis. 2010;28:783-791. [PMID: 21525763 DOI: 10.1159/000324286] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
208 Ratziu V, Martin L, Fedchuk L, Poynard T. Can nonalcoholic steatohepatitis be diagnosed without liver biopsy? Biomark Med 2009;3:353-61. [PMID: 20477484 DOI: 10.2217/bmm.09.36] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
209 Lane SL, Doyle AS, Bales ES, Houck JA, Lorca RA, Moore LG, Julian CG. Peroxisome proliferator-activated receptor gamma blunts endothelin-1-mediated contraction of the uterine artery in a murine model of high-altitude pregnancy. FASEB J 2020;34:4283-92. [PMID: 31970838 DOI: 10.1096/fj.201902264RR] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
210 Gkolfakis P, Dimitriadis G, Triantafyllou K. Gut microbiota and non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 2015;14:572-81. [PMID: 26663004 DOI: 10.1016/s1499-3872(15)60026-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 22] [Article Influence: 8.8] [Reference Citation Analysis]
211 Li P, Fan C, Cai Y, Fang S, Zeng Y, Zhang Y, Lin X, Zhang H, Xue Y, Guan M. Transplantation of brown adipose tissue up-regulates miR-99a to ameliorate liver metabolic disorders in diabetic mice by targeting NOX4. Adipocyte 2020;9:57-67. [PMID: 32000567 DOI: 10.1080/21623945.2020.1721970] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
212 Adiels M, Olofsson SO, Taskinen MR, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:1225-36. [PMID: 18565848 DOI: 10.1161/ATVBAHA.107.160192] [Cited by in Crossref: 470] [Cited by in F6Publishing: 197] [Article Influence: 36.2] [Reference Citation Analysis]
213 Rodrigues T, Matafome P, Seiça R. A vascular piece in the puzzle of adipose tissue dysfunction: mechanisms and consequences. Archives of Physiology and Biochemistry 2013;120:1-11. [DOI: 10.3109/13813455.2013.838971] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
214 Fu J, Hou Y, Xue P, Wang H, Xu Y, Qu W, Zhang Q, Pi J. Nrf2 in Type 2 diabetes and diabetic complications: Yin and Yang. Current Opinion in Toxicology 2016;1:9-19. [DOI: 10.1016/j.cotox.2016.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
215 Papandreou D, Rousso I, Mavromichalis I. Update on non-alcoholic fatty liver disease in children. Clinical Nutrition 2007;26:409-15. [DOI: 10.1016/j.clnu.2007.02.002] [Cited by in Crossref: 77] [Cited by in F6Publishing: 81] [Article Influence: 5.5] [Reference Citation Analysis]
216 Bang KB, Cho YK. Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med. 2015;5:7-13. [PMID: 26528424 DOI: 10.15280/jlm.2015.5.1.7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
217 Bozzetto L, Annuzzi G, Ragucci M, Di Donato O, Della Pepa G, Della Corte G, Griffo E, Anniballi G, Giacco A, Mancini M, Rivellese AA. Insulin resistance, postprandial GLP-1 and adaptive immunity are the main predictors of NAFLD in a homogeneous population at high cardiovascular risk. Nutr Metab Cardiovasc Dis 2016;26:623-9. [PMID: 27134062 DOI: 10.1016/j.numecd.2016.01.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
218 Wójcik K, Jabłonowska E, Omulecka A, Piekarska A. Insulin resistance, adipokine profile and hepatic expression of SOCS-3 gene in chronic hepatitis C. World J Gastroenterol 2014;20:10449-56. [PMID: 25132761 DOI: 10.3748/wjg.v20.i30.10449] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
219 Carulli L, Canedi I, Rondinella S, Lombardini S, Ganazzi D, Fargion S, De Palma M, Lonardo A, Ricchi M, Bertolotti M, Carulli N, Loria P. Genetic polymorphisms in non-alcoholic fatty liver disease: Interleukin-6−174G/C polymorphism is associated with non-alcoholic steatohepatitis. Digestive and Liver Disease 2009;41:823-8. [DOI: 10.1016/j.dld.2009.03.005] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
220 Armandi A, Rosso C, Caviglia GP, Bugianesi E. Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. Metabolites 2021;11:155. [PMID: 33800465 DOI: 10.3390/metabo11030155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
221 Kaya D, Kaji K, Tsuji Y, Yamashita S, Kitagawa K, Ozutsumi T, Fujinaga Y, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H. TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. Cells 2019;8:E1153. [PMID: 31561561 DOI: 10.3390/cells8101153] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
222 Lee YJ, Yu JH, Kim W, Kim J. New mechanisms contributing to hepatic steatosis: glucose, insulin, and lipid signaling. Animal Cells and Systems 2014;18:77-82. [DOI: 10.1080/19768354.2014.906502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
223 Gamas L, Matafome P, Seiça R. Irisin and Myonectin Regulation in the Insulin Resistant Muscle: Implications to Adipose Tissue: Muscle Crosstalk. J Diabetes Res 2015;2015:359159. [PMID: 26075283 DOI: 10.1155/2015/359159] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
224 Sun DQ, Wu SJ, Liu WY, Lu QD, Zhu GQ, Shi KQ, Braddock M, Song D, Zheng MH. Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. Expert Opin Ther Targets 2016;20:375-87. [PMID: 26419119 DOI: 10.1517/14728222.2016.1096930] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
225 Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Digestive and Liver Disease 2015;47:181-90. [DOI: 10.1016/j.dld.2014.09.020] [Cited by in Crossref: 371] [Cited by in F6Publishing: 316] [Article Influence: 61.8] [Reference Citation Analysis]
226 Nishimura N, Kitade M, Noguchi R, Namisaki T, Moriya K, Takeda K, Okura Y, Aihara Y, Douhara A, Kawaratani H, Asada K, Yoshiji H. Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long–Evans Tokushima fatty rats. J Gastroenterol 2016;51:1141-9. [DOI: 10.1007/s00535-016-1200-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
227 Rosso C, Caviglia GP, Ciruolo M, Ciancio A, Younes R, Olivero A, Giordanino C, Troshina G, Abate ML, Rizzetto M, Pellicano R, Saracco GM, Bugianesi E, Smedile A. Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. Minerva Med 2019;110:401-9. [PMID: 31081312 DOI: 10.23736/S0026-4806.19.06108-1] [Cited by in Crossref: 13] [Article Influence: 6.5] [Reference Citation Analysis]
228 Loria P, Lonardo A, Targher G. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clin Sci (Lond). 2008;115:1-12. [PMID: 19016656 DOI: 10.1042/cs20070311] [Cited by in Crossref: 47] [Cited by in F6Publishing: 14] [Article Influence: 3.9] [Reference Citation Analysis]
229 Wu H, Chen W, Cheng K, Ku P, Yeh C, Cheng J. Oleic acid activates peroxisome proliferator-activated receptor δ to compensate insulin resistance in steatotic cells. The Journal of Nutritional Biochemistry 2012;23:1264-70. [DOI: 10.1016/j.jnutbio.2011.07.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
230 Negro F. Insulin resistance and HCV: will new knowledge modify clinical management? J Hepatol 2006;45:514-9. [PMID: 16901576 DOI: 10.1016/j.jhep.2006.07.011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
231 Petersen MC, Madiraju AK, Gassaway BM, Marcel M, Nasiri AR, Butrico G, Marcucci MJ, Zhang D, Abulizi A, Zhang XM, Philbrick W, Hubbard SR, Jurczak MJ, Samuel VT, Rinehart J, Shulman GI. Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance. J Clin Invest 2016;126:4361-71. [PMID: 27760050 DOI: 10.1172/JCI86013] [Cited by in Crossref: 108] [Cited by in F6Publishing: 68] [Article Influence: 21.6] [Reference Citation Analysis]
232 Goodman ZD. The Impact of Obesity on Liver Histology. Clinics in Liver Disease 2014;18:33-40. [DOI: 10.1016/j.cld.2013.09.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
233 Yatsuji S, Hashimoto E, Tobari M, Tokushige K, Shiratori K. Influence of age and gender in Japanese patients with non-alcoholic steatohepatitis. Hepatol Res. 2007;37:1034-1043. [PMID: 17610504 DOI: 10.1111/j.1872-034x.2007.00156.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
234 Zheng MH, Shi KQ, Fan YC, Liu WY, Lin XF, Li LF, Chen YP. Upper limits of normal for serum alanine aminotransferase levels in Chinese Han population. PLoS One 2012;7:e43736. [PMID: 22962588 DOI: 10.1371/journal.pone.0043736] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
235 Sechi LA, Soardo G, Catena C. Nonalcoholic fatty liver and left ventricular remodelling: now the prospective evidence. J Hypertens 2021;39:864-6. [PMID: 33824256 DOI: 10.1097/HJH.0000000000002750] [Reference Citation Analysis]
236 d'Angelo M, Castelli V, Tupone MG, Catanesi M, Antonosante A, Dominguez-Benot R, Ippoliti R, Cimini AM, Benedetti E. Lifestyle and Food Habits Impact on Chronic Diseases: Roles of PPARs. Int J Mol Sci 2019;20:E5422. [PMID: 31683535 DOI: 10.3390/ijms20215422] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
237 Ratziu V, Zelber-sagi S. Pharmacologic Therapy of Non-Alcoholic Steatohepatitis. Clinics in Liver Disease 2009;13:667-88. [DOI: 10.1016/j.cld.2009.07.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
238 Kaur S U, Oyeyemi BF, Shet A, Gopalan BP, D H, Bhavesh NS, Tandon R. Plasma metabolomic study in perinatally HIV-infected children using 1H NMR spectroscopy reveals perturbed metabolites that sustain during therapy. PLoS One 2020;15:e0238316. [PMID: 32866201 DOI: 10.1371/journal.pone.0238316] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Hassan MM, Kaseb A, Etzel CJ, El-Serag H, Spitz MR, Chang P, Hale KS, Liu M, Rashid A, Shama M, Abbruzzese JL, Loyer EM, Kaur H, Hassabo HM, Vauthey JN, Wray CJ, Hassan BS, Patt YZ, Hawk E, Soliman KM, Li D. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013;52 Suppl 1:E139-E147. [PMID: 23776098 DOI: 10.1002/mc.22057] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
240 Leclercq IA, Horsmans Y. Nonalcoholic fatty liver disease: the potential role of nutritional management. Curr Opin Clin Nutr Metab Care 2008;11:766-73. [PMID: 18827582 DOI: 10.1097/MCO.0b013e328312c353] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
241 Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009;2009:831670. [PMID: 19753129 DOI: 10.1155/2009/831670] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 5.9] [Reference Citation Analysis]
242 Nobili V, Alisi A, Raponi M. Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. World J Gastroenterol. 2009;15:6017-6022. [PMID: 20027672 DOI: 10.3748/wjg.15.6017] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
243 Carnagarin R, Tan K, Adams L, Matthews VB, Kiuchi MG, Marisol Lugo Gavidia L, Lambert GW, Lambert EA, Herat LY, Schlaich MP. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-A Condition Associated with Heightened Sympathetic Activation. Int J Mol Sci 2021;22:4241. [PMID: 33921881 DOI: 10.3390/ijms22084241] [Reference Citation Analysis]
244 Park B, Jung KW, Oh CM, Choi KS, Suh M, Jun JK. Prevalence of and factors influencing impaired glucose tolerance among hepatitis B carriers: a nationwide cross-sectional study in the Republic of Korea. Medicine (Baltimore) 2014;93:e91. [PMID: 25365406 DOI: 10.1097/MD.0000000000000091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
245 Petta S, Cammà C, Di Marco V, Alessi N, Barbaria F, Cabibi D, Caldarella R, Ciminnisi S, Licata A, Massenti MF, Mazzola A, Tarantino G, Marchesini G, Craxì A. Retinol‐binding protein 4: A new marker of virus‐induced steatosis in patients infected with hepatitis c virus genotype 1. Hepatology 2008;48:28-37. [DOI: 10.1002/hep.22316] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
246 Caballería L, Pera G, Rodríguez L, Auladell MA, Bernad J, Canut S, Torán P. Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population: influence of the diagnostic criteria used. Eur J Gastroenterol Hepatol. 2012;24:1007-1011. [PMID: 22668875 DOI: 10.1097/meg.0b013e328355b87f] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
247 Scribner KB, Pawlak DB, Ludwig DS. Hepatic steatosis and increased adiposity in mice consuming rapidly vs. slowly absorbed carbohydrate. Obesity (Silver Spring) 2007;15:2190-9. [PMID: 17890486 DOI: 10.1038/oby.2007.260] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 4.2] [Reference Citation Analysis]
248 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908-922. [PMID: 29967350 DOI: 10.1038/s41591-018-0104-9] [Cited by in Crossref: 777] [Cited by in F6Publishing: 657] [Article Influence: 259.0] [Reference Citation Analysis]
249 Gogia S, Neuschwander-tetri BA. Unexplained CK elevations in patients with nonalcoholic steatohepatitis. Liver Int 2006;26:899-900. [DOI: 10.1111/j.1478-3231.2006.01299.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
250 Li M, Zhou H, Guan Y, Peng H, Wang S, Zhang P, Su B. Positive hepatitis B surface antibody is associated with reduced risk of diabetes mellitus in retired female Chinese workers. J Diabetes 2016;8:158-61. [PMID: 26016384 DOI: 10.1111/1753-0407.12317] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
251 Sinn DH, Gwak GY, Park HN, Kim JE, Min YW, Kim KM, Kim YJ, Choi MS, Lee JH, Koh KC. Ultrasonographically detected non-alcoholic fatty liver disease is an independent predictor for identifying patients with insulin resistance in non-obese, non-diabetic middle-aged Asian adults. Am J Gastroenterol. 2012;107:561-567. [PMID: 22108448 DOI: 10.1038/ajg.2011.400] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 7.3] [Reference Citation Analysis]
252 Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015;1. [DOI: 10.1038/nrdp.2015.80] [Cited by in Crossref: 302] [Cited by in F6Publishing: 258] [Article Influence: 50.3] [Reference Citation Analysis]
253 Cong W, Tao R, Tian J, Liu G, Ye F. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sciences 2008;82:983-90. [DOI: 10.1016/j.lfs.2008.01.022] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
254 Saeedi Borujeni MJ, Esfandiary E, Ghanadian M, Valiani A, Baradaran A, Yazdani A. Alterations in lipid peroxidation, lipid profile, insulin sensitivity, and hepatic histopathological changes in diabetic rats following the treatment with Salvadora persica. J Cell Biochem 2019;120:3696-708. [DOI: 10.1002/jcb.27649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
255 Almeda-valdés P, Cuevas-ramos D, Alberto Aguilar-salinas C. Metabolic syndrome and non-alcoholic fatty liver disease. Annals of Hepatology 2009;8:S18-24. [DOI: 10.1016/s1665-2681(19)31822-8] [Cited by in Crossref: 99] [Article Influence: 8.3] [Reference Citation Analysis]
256 Fraenkel E, Takács R, Hamvas J, Lengyel G, Fehér J. [Common occurrence of non-alcoholic fatty liver disease and cholecystolithiasis]. Orv Hetil. 2007;148:793-798. [PMID: 17452309 DOI: 10.1556/hmj.1.2007.3.8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
257 Daryani NE, Daryani NE, Alavian SM, Zare A, Fereshtehnejad SM, Keramati MR, Pashaei MR, Habibollahi P. Non-alcoholic steatohepatitis and influence of age and gender on histopathologic findings. World J Gastroenterol. 2010;16:4169-4175. [PMID: 20806434 DOI: 10.3748/wjg.v16.i33.4169] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
258 Zhang T, Zhang Y, Zhang C, Tang F, Li H, Zhang Q, Lin H, Wu S, Liu Y, Xue F. Prediction of metabolic syndrome by non-alcoholic fatty liver disease in northern urban Han Chinese population: a prospective cohort study. PLoS One. 2014;9:e96651. [PMID: 24801211 DOI: 10.1371/journal.pone.0096651] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
259 Sun S, Hanzawa F, Umeki M, Ikeda S, Mochizuki S, Oda H. Time-restricted feeding suppresses excess sucrose-induced plasma and liver lipid accumulation in rats. PLoS One 2018;13:e0201261. [PMID: 30110343 DOI: 10.1371/journal.pone.0201261] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
260 Kwon JH, Park ST, Kim GD, You CR, Kim JD, Woo HY, Jang JW, Kim CW, Bae SH, Choi JY, Yoon SK. The value of serum retinol-binding protein 4 levels for determining disease severity in patients with chronic liver disease. Korean J Hepatol 2009;15:59. [DOI: 10.3350/kjhep.2009.15.1.59] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
261 Fallo F, Pozza AD, Sonino N, Federspil G, Ermani M, Baroselli S, Catena C, Soardo G, Carretta R, Belgrado D, Fabris B, Sechi LA. Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients. Journal of Hypertension 2008;26:2191-7. [DOI: 10.1097/hjh.0b013e32830dfe4b] [Cited by in Crossref: 30] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
262 Ratziu V, Pienar L. Pharmacological therapy for non-alcoholic steatohepatitis: How efficient are thiazolidinediones? Hepatol Res 2011;41:687-95. [PMID: 21711428 DOI: 10.1111/j.1872-034X.2011.00825.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
263 Swaminathan K, Kumar SM, Clemens DL, Dey A. Inhibition of CYP2E1 leads to decreased advanced glycated end product formation in high glucose treated ADH and CYP2E1 over-expressing VL-17A cells. Biochimica et Biophysica Acta (BBA) - General Subjects 2013;1830:4407-16. [DOI: 10.1016/j.bbagen.2013.05.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
264 Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, Smirčić Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:18070-91. [PMID: 25561778 DOI: 10.3748/wjg.v20.i48.18070] [Cited by in CrossRef: 174] [Cited by in F6Publishing: 144] [Article Influence: 29.0] [Reference Citation Analysis]
265 Tomita K, Freeman BL, Bronk SF, LeBrasseur NK, White TA, Hirsova P, Ibrahim SH. CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis. Sci Rep 2016;6:28786. [PMID: 27349927 DOI: 10.1038/srep28786] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 11.2] [Reference Citation Analysis]
266 Zhu Y, Xiao X, Li G, Bu J, Zhou W, Zhou S. Isoflurane anesthesia induces liver injury by regulating the expression of insulin-like growth factor 1. Exp Ther Med 2017;13:1608-13. [PMID: 28413517 DOI: 10.3892/etm.2017.4157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
267 Safhi MM, Alam MF, Sivakumar SM, Anwer T. Hepatoprotective Potential of Sargassum muticum against STZ-Induced Diabetic Liver Damage in Wistar Rats by Inhibiting Cytokines and the Apoptosis Pathway. Anal Cell Pathol (Amst) 2019;2019:7958701. [PMID: 30937278 DOI: 10.1155/2019/7958701] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
268 van den Berg EH, Gruppen EG, Blokzijl H, Bakker SJL, Dullaart RPF. Higher Sodium Intake Assessed by 24 Hour Urinary Sodium Excretion Is Associated with Non-Alcoholic Fatty Liver Disease: The PREVEND Cohort Study. J Clin Med 2019;8:E2157. [PMID: 31817623 DOI: 10.3390/jcm8122157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
269 Ashino NG, Saito KN, Souza FD, Nakutz FS, Roman EA, Velloso LA, Torsoni AS, Torsoni MA. Maternal high-fat feeding through pregnancy and lactation predisposes mouse offspring to molecular insulin resistance and fatty liver. J Nutr Biochem. 2012;23:341-348. [PMID: 21543214 DOI: 10.1016/j.jnutbio.2010.12.011] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 11.3] [Reference Citation Analysis]
270 Fallo F, Dalla Pozza A, Sonino N, Lupia M, Tona F, Federspil G, Ermani M, Catena C, Soardo G, Di Piazza L. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis. 2009;19:646-653. [PMID: 19278843 DOI: 10.1016/j.numecd.2008.12.007] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 5.6] [Reference Citation Analysis]
271 Schattenberg JM, Schuchmann M. Diabetes and apoptosis: liver. Apoptosis 2009;14:1459-71. [PMID: 19544096 DOI: 10.1007/s10495-009-0366-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
272 Cotrim HP, Parise ER, Oliveira CP, Leite N, Martinelli A, Galizzi J, de Càssia Silva R, Mattos Â, Pereira L, Amorim W, Ivantes C, Souza F, Costa M, Maia L, Pessoa M, Oliveira F. Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile. Annals of Hepatology 2011;10:33-7. [DOI: 10.1016/s1665-2681(19)31584-4] [Cited by in Crossref: 33] [Article Influence: 3.3] [Reference Citation Analysis]
273 Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, Dhiman RK, Jayakumar RV, Madan K, Misra SP, Mishra H, Modi SK, Muruganathan A, Saboo B, Sahay R, Upadhyay R. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J ClinExpHepatol. 2015;5:51-68. [PMID: 25941433 DOI: 10.1016/j.jceh.2015.02.006] [Cited by in Crossref: 69] [Cited by in F6Publishing: 52] [Article Influence: 11.5] [Reference Citation Analysis]
274 Raso GM, Esposito E, Iacono A, Pacilio M, Cuzzocrea S, Canani RB, Calignano A, Meli R. Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat. Eur J Pharmacol 2009;604:125-31. [PMID: 19135440 DOI: 10.1016/j.ejphar.2008.12.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
275 Gao Y, Tian R, Liu H, Xue H, Zhang R, Han S, Ji L, Huang W, Zhan J, You Y. Research progress on intervention effect and mechanism of protocatechuic acid on nonalcoholic fatty liver disease. Crit Rev Food Sci Nutr 2021;:1-23. [PMID: 34142875 DOI: 10.1080/10408398.2021.1939265] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
276 Li H, Deng X, Li Z, Luo C, Liu J, Wang Y. Variation of serum monocyte chemoattractant protein-1 in patients with diabetes and metabolic syndrome. J Huazhong Univ Sci Technolog Med Sci 2011;31:312-6. [PMID: 21671170 DOI: 10.1007/s11596-011-0373-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
277 Kothari V, Luo Y, Tornabene T, O'neill AM, Greene MW, Geetha T, Babu JR. High fat diet induces brain insulin resistance and cognitive impairment in mice. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2017;1863:499-508. [DOI: 10.1016/j.bbadis.2016.10.006] [Cited by in Crossref: 101] [Cited by in F6Publishing: 86] [Article Influence: 25.3] [Reference Citation Analysis]
278 Ben-Shlomo S, Einstein FH, Zvibel I, Atias D, Shlomai A, Halpern Z, Barzilai N, Fishman S. Perinephric and epididymal fat affect hepatic metabolism in rats. Obesity (Silver Spring) 2012;20:151-6. [PMID: 21818154 DOI: 10.1038/oby.2011.261] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
279 Hsiao PJ, Chen ZC, Hung WW, Yang YH, Lee MY, Huang JF, Kuo KK. Risk interaction of obesity, insulin resistance and hormone-sensitive lipase promoter polymorphisms (LIPE-60 C > G) in the development of fatty liver. BMC Med Genet 2013;14:54. [PMID: 23688034 DOI: 10.1186/1471-2350-14-54] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
280 Karimi-Sales E, Mohaddes G, Alipour MR. Hepatoprotection of capsaicin in alcoholic and non-alcoholic fatty liver diseases. Arch Physiol Biochem 2021;:1-11. [PMID: 34396890 DOI: 10.1080/13813455.2021.1962913] [Reference Citation Analysis]
281 Cui W, Li J, Chen X, Mao Q, Wei X, Wen X, Yang J, Wang Q. Ilexgenin A Obtained from Ilex hainanensis Merr. Improves Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats: Ilexgenin A Improves Diet-Induced NAFLD. Drug Dev Res 2013;74:227-36. [DOI: 10.1002/ddr.21066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
282 Merriman RB. Nonalcoholic fatty liver disease and HIV infection. Curr HIV/AIDS Rep 2006;3:113-7. [PMID: 16970837 DOI: 10.1007/BF02696654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
283 Popov VB, Lim JK. Impact of Insulin-Sensitizing Agents on Risk for Liver Cancer and Liver-Related Death in Diabetic Patients with Compensated Hepatitis C Cirrhosis. The Journal of Clinical Endocrinology & Metabolism 2011;96:2398-400. [DOI: 10.1210/jc.2011-1875] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
284 Matthew Morris E, Fletcher JA, Thyfault JP, Scott Rector R. The role of angiotensin II in nonalcoholic steatohepatitis. Molecular and Cellular Endocrinology 2013;378:29-40. [DOI: 10.1016/j.mce.2012.04.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
285 Tveden-nyborg P, Birck MM, Ipsen DH, Thiessen T, Feldmann LDB, Lindblad MM, Jensen HE, Lykkesfeldt J. Diet-induced dyslipidemia leads to nonalcoholic fatty liver disease and oxidative stress in guinea pigs. Translational Research 2016;168:146-60. [DOI: 10.1016/j.trsl.2015.10.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
286 Ruffillo G, Fassio E, Alvarez E, Landeira G, Longo C, Domínguez N, Gualano G. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. Journal of Hepatology 2011;54:160-3. [DOI: 10.1016/j.jhep.2010.06.028] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
287 Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2007;13:3540-3553. [PMID: 17659704 DOI: 10.3748/wjg.v13.i26.3540] [Cited by in CrossRef: 151] [Cited by in F6Publishing: 138] [Article Influence: 10.8] [Reference Citation Analysis]
288 Lautamäki R, Borra R, Iozzo P, Komu M, Lehtimäki T, Salmi M, Jalkanen S, Airaksinen KEJ, Knuuti J, Parkkola R, Nuutila P. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. American Journal of Physiology-Endocrinology and Metabolism 2006;291:E282-90. [DOI: 10.1152/ajpendo.00604.2005] [Cited by in Crossref: 103] [Cited by in F6Publishing: 98] [Article Influence: 6.9] [Reference Citation Analysis]
289 Bugianesi E, Vanni E, Marchesini G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr Diab Rep. 2007;7:175-180. [PMID: 17547834 DOI: 10.1007/s11892-007-0029-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
290 Holtenius P, Holtenius K. A model to estimate insulin sensitivity in dairy cows. Acta Vet Scand 2007;49:29. [PMID: 17931417 DOI: 10.1186/1751-0147-49-29] [Cited by in Crossref: 121] [Cited by in F6Publishing: 89] [Article Influence: 8.6] [Reference Citation Analysis]
291 Li XX, Lu XY, Zhang SJ, Chiu AP, Lo LH, Largaespada DA, Chen QB, Keng VW. Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation. Biomed Pharmacother 2019;111:68-75. [PMID: 30576936 DOI: 10.1016/j.biopha.2018.12.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
292 Soresi M, Cabibi D, Giglio RV, Martorana S, Guercio G, Porcasi R, Terranova A, Lazzaro LA, Emma MR, Augello G, Cervello M, Pantuso G, Montalto G, Giannitrapani L. The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods.Biomed Res Int. 2020;2020:5023157. [PMID: 32420347 DOI: 10.1155/2020/5023157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
293 Ni Y, Ni L, Zhuge F, Fu Z. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2020;64:e2000375. [PMID: 32738185 DOI: 10.1002/mnfr.202000375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
294 van der Poorten D, George J. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clin Liver Dis. 2008;12:805-824, ix. [PMID: 18984468 DOI: 10.1016/j.cld.2008.07.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
295 Bugianesi E, Bellentani S, Bedogni G, Tiribelli C. Clinical update on non-alcoholic fatty liver disease and steatohepatitis. Annals of Hepatology 2008;7:157-60. [DOI: 10.1016/s1665-2681(19)31873-3] [Cited by in Crossref: 9] [Article Influence: 0.7] [Reference Citation Analysis]
296 Naveau S, Dobrin AS, Balian A, Njiké-Nakseu M, Nohra P, Asnacios A, Prévot S, Perlemuter G. Body fat distribution and risk factors for fibrosis in patients with alcoholic liver disease. Alcohol Clin Exp Res 2013;37:332-8. [PMID: 22958117 DOI: 10.1111/j.1530-0277.2012.01927.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
297 Wijesundera KK, Izawa T, Tennakoon AH, Golbar HM, Tanaka M, Kuwamura M, Yamate J. M1-/M2-macrophage polarization in pseudolobules consisting of adipohilin-rich hepatocytes in thioacetamide (TAA)-induced rat hepatic cirrhosis. Exp Mol Pathol. 2016;101:133-142. [PMID: 27453055 DOI: 10.1016/j.yexmp.2016.07.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
298 Gao TT, Qin ZL, Ren H, Zhao P, Qi ZT. Inhibition of IRS-1 by hepatitis C virus infection leads to insulin resistance in a PTEN-dependent manner. Virol J 2015;12:12. [PMID: 25645159 DOI: 10.1186/s12985-015-0241-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
299 Abenavoli L, Milic N, Di Renzo L, Preveden T, Medić-Stojanoska M, De Lorenzo A. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol 2016;22:7006-16. [PMID: 27610012 DOI: 10.3748/wjg.v22.i31.7006] [Cited by in CrossRef: 95] [Cited by in F6Publishing: 85] [Article Influence: 23.8] [Reference Citation Analysis]
300 Hübscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology. 2006;49:450-465. [PMID: 17064291 DOI: 10.1111/j.1365-2559.2006.02416.x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 157] [Article Influence: 12.0] [Reference Citation Analysis]
301 Magalhães GC, Feitoza FM, Moreira SB, Carmo AV, Souto FJ, Reis SR, Martins MS, Gomes da Silva MH. Hypoadiponectinaemia in nonalcoholic fatty liver disease obese women is associated with infrequent intake of dietary sucrose and fatty foods. J Hum Nutr Diet 2014;27 Suppl 2:301-12. [PMID: 23790128 DOI: 10.1111/jhn.12110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
302 Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KS, Chisholm DJ, George J. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology. 2009;49:1926-1934. [PMID: 19475694 DOI: 10.1002/hep.22896] [Cited by in Crossref: 115] [Cited by in F6Publishing: 105] [Article Influence: 9.6] [Reference Citation Analysis]
303 Asrih M, Jornayvaz FR. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Molecular and Cellular Endocrinology 2015;418:55-65. [DOI: 10.1016/j.mce.2015.02.018] [Cited by in Crossref: 150] [Cited by in F6Publishing: 143] [Article Influence: 25.0] [Reference Citation Analysis]
304 Ikuta T, Kanno K, Arihiro K, Matsuda S, Kishikawa N, Fujita K, Tazuma S. Spontaneously hypertensive rats develop pronounced hepatic steatosis induced by choline-deficient diet: Evidence for hypertension as a potential enhancer in non-alcoholic steatohepatitis. Hepatol Res 2012;42:310-20. [PMID: 22176027 DOI: 10.1111/j.1872-034X.2011.00920.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
305 Li Z, Yu P, Wu J, Tao F, Zhou J. Transcriptional Regulation of Early Growth Response Gene-1 (EGR1) is Associated with Progression of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients with Insulin Resistance. Med Sci Monit 2019;25:2293-3004. [PMID: 31013265 DOI: 10.12659/MSM.914044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
306 El-Zayadi AR. Hepatic steatosis: a benign disease or a silent killer. World J Gastroenterol. 2008;14:4120-4126. [PMID: 18636654 DOI: 10.3748/wjg.14.4120] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
307 Hansen HH, Ægidius HM, Oró D, Evers SS, Heebøll S, Eriksen PL, Thomsen KL, Bengtsson A, Veidal SS, Feigh M, Suppli MP, Knop FK, Grønbæk H, Miranda D, Trevaskis JL, Vrang N, Jelsing J, Rigbolt KTG. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol 2020;20:210. [PMID: 32631250 DOI: 10.1186/s12876-020-01356-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
308 Serfaty L. Pioglitazone: The beginning of a new era for NASH? Journal of Hepatology 2007;47:160-2. [DOI: 10.1016/j.jhep.2007.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
309 Shabani P, Emamgholipour S, Doosti M. CTRP1 in Liver Disease. Elsevier; 2017. pp. 1-23. [DOI: 10.1016/bs.acc.2016.10.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
310 Borén J, Taskinen M, Adiels M. Kinetic studies to investigate lipoprotein metabolism: Key Symposium: Kinetic studies to investigate lipoprotein metabolism. Journal of Internal Medicine 2012;271:166-73. [DOI: 10.1111/j.1365-2796.2011.02497.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
311 Wang XC, Zhan XR, Li XY, Yu JJ, Liu XM. MicroRNA-185 regulates expression of lipid metabolism genes and improves insulin sensitivity in mice with non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:17914-17923. [PMID: 25548489 DOI: 10.3748/wjg.v20.i47.17914] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
312 Sung KC, Lee MY, Lee JY, Lee SH, Kim YB, Song WJ, Huh JH, Park JS, Shin JH, Seo MH, Kim SH, Kim SH. Natural course of fatty liver in 36,195 South Korean adults. Sci Rep 2019;9:9062. [PMID: 31308382 DOI: 10.1038/s41598-019-44738-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
313 Milic S, Štimac D. Nonalcoholic Fatty Liver Disease/Steatohepatitis: Epidemiology, Pathogenesis, Clinical Presentation and Treatment. Dig Dis 2012;30:158-62. [DOI: 10.1159/000336669] [Cited by in Crossref: 124] [Cited by in F6Publishing: 119] [Article Influence: 13.8] [Reference Citation Analysis]
314 Amrutkar M, Cansby E, Nuñez-Durán E, Pirazzi C, Ståhlman M, Stenfeldt E, Smith U, Borén J, Mahlapuu M. Protein kinase STK25 regulates hepatic lipid partitioning and progression of liver steatosis and NASH. FASEB J 2015;29:1564-76. [PMID: 25609431 DOI: 10.1096/fj.14-264937] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
315 Yamada T, Fukatsu M, Suzuki S, Yoshida T, Tokudome S, Joh T. Alcohol drinking may not be a major risk factor for fatty liver in Japanese undergoing a health checkup. Dig Dis Sci. 2010;55:176-182. [PMID: 19156520 DOI: 10.1007/s10620-008-0693-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
316 Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology. 2006;43:1168; author reply 1168-1169. [PMID: 16628642 DOI: 10.1002/hep.21125] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
317 Wang Q, Tikhonenko M, Bozack SN, Lydic TA, Yan L, Panchy NL, McSorley KM, Faber MS, Yan Y, Boulton ME, Grant MB, Busik JV. Changes in the daily rhythm of lipid metabolism in the diabetic retina. PLoS One 2014;9:e95028. [PMID: 24736612 DOI: 10.1371/journal.pone.0095028] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
318 Ferreira DM, Simão AL, Rodrigues CM, Castro RE. Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease. FEBS J 2014;281:2503-24. [PMID: 24702768 DOI: 10.1111/febs.12806] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
319 Deng Y, Palmeri ML, Rouze NC, Rosenzweig SJ, Abdelmalek MF, Nightingale KR. Analyzing the Impact of Increasing Mechanical Index and Energy Deposition on Shear Wave Speed Reconstruction in Human Liver. Ultrasound Med Biol 2015;41:1948-57. [PMID: 25896024 DOI: 10.1016/j.ultrasmedbio.2015.02.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
320 Gäbele E, Dostert K, Dorn C, Patsenker E, Stickel F, Hellerbrand C. A new model of interactive effects of alcohol and high-fat diet on hepatic fibrosis. Alcohol Clin Exp Res. 2011;35:1361-1367. [PMID: 21463337 DOI: 10.1111/j.1530-0277.2011.01472.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 5.4] [Reference Citation Analysis]
321 Scorletti E, Byrne CD. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. Mol Aspects Med 2018;64:135-46. [PMID: 29544992 DOI: 10.1016/j.mam.2018.03.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 15.7] [Reference Citation Analysis]
322 Chung GE, Yim JY, Kim D, Kwak MS, Yang JI, Park B, An SJ, Kim JS. Nonalcoholic Fatty Liver Disease Is Associated with Benign Prostate Hyperplasia. J Korean Med Sci 2020;35:e164. [PMID: 32508064 DOI: 10.3346/jkms.2020.35.e164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
323 Ezzat WM, Ragab S, Ismail NA, Elhosary YA, Elbaky AMNEA, Farouk H, Rasheed IA. Frequency of non-alcoholic fatty liver disease in overweight/obese children and adults: Clinical, sonographic picture and biochemical assessment. Journal of Genetic Engineering and Biotechnology 2012;10:221-7. [DOI: 10.1016/j.jgeb.2012.05.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
324 Chen PJ, Cai SP, Huang C, Meng XM, Li J. Protein tyrosine phosphatase 1B (PTP1B): A key regulator and therapeutic target in liver diseases. Toxicology 2015;337:10-20. [PMID: 26299811 DOI: 10.1016/j.tox.2015.08.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
325 Oh HJ, Kim TH, Sohn YW, Kim YS, Oh YR, Cho EY, Shim SY, Shin SR, Han AL, Yoon SJ. Association of serum alanine aminotransferase and γ-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease. Korean J Hepatol. 2011;17:27-36. [PMID: 21494075 DOI: 10.3350/kjhep.2011.17.1.27] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
326 Rabiee B, Roozafzai F, Hemasi GR, Poustchi H, Keyvani H, Khonsari MR, Ajdarkosh H, Maadi M, Sima Saeedian F, Zamani F. The Prevalence of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus in an Iranian Population. Middle East J Dig Dis 2017;9:86-93. [PMID: 28638584 DOI: 10.15171/mejdd.2017.56] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
327 Yamamoto H, Kanno K, Ikuta T, Arihiro K, Sugiyama A, Kishikawa N, Tazuma S. Enhancing hepatic fibrosis in spontaneously hypertensive rats fed a choline-deficient diet: a follow-up report on long-term effects of oxidative stress in non-alcoholic fatty liver disease. J Hepatobiliary Pancreat Sci 2016;23:260-9. [DOI: 10.1002/jhbp.333] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
328 De Fré CH, De Fré MA, Kwanten WJ, Op de Beeck BJ, Van Gaal LF, Francque SM. Sarcopenia in patients with non-alcoholic fatty liver disease: is it a clinically significant entity?: Sarcopenia in patients with NAFLD. Obesity Reviews 2019;20:353-63. [DOI: 10.1111/obr.12776] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
329 Kuo YC, Chen IY, Chang SC, Wu SC, Hung TM, Lee PH, Shimotohno K, Chang MF. Hepatitis C virus NS5A protein enhances gluconeogenesis through upregulation of Akt-/JNK-PEPCK signalling pathways. Liver Int 2014;34:1358-68. [PMID: 25360475 DOI: 10.1111/liv.12389] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
330 Cameron AM, Busuttil RW. The status of liver transplantation for hepatitis C. Expert Opinion on Biological Therapy 2006;6:993-1002. [DOI: 10.1517/14712598.6.10.993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
331 García-Monzón C, Lo Iacono O, Mayoral R, González-Rodríguez A, Miquilena-Colina ME, Lozano-Rodríguez T, García-Pozo L, Vargas-Castrillón J, Casado M, Boscá L. Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. J Hepatol. 2011;54:142-152. [PMID: 20888662 DOI: 10.1016/j.jhep.2010.06.021] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
332 Wong VW, Hui AY, Tsang SW, Chan JL, Wong GL, Chan AW, So WY, Cheng AY, Tong PC, Chan FK. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24:1215-1222. [PMID: 17014580 DOI: 10.1111/j.1365-2036.2006.03112.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 5.3] [Reference Citation Analysis]
333 Wree A, Schlattjan M, Bechmann LP, Claudel T, Sowa JP, Stojakovic T, Scharnagl H, Köfeler H, Baba HA, Gerken G, Feldstein AE, Trauner M, Canbay A. Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. Metabolism 2014;63:1542-52. [PMID: 25267016 DOI: 10.1016/j.metabol.2014.09.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 8.9] [Reference Citation Analysis]
334 Decara JM, Pavón FJ, Suárez J, Romero-Cuevas M, Baixeras E, Vázquez M, Rivera P, Gavito AL, Almeida B, Joglar J, de la Torre R, Rodríguez de Fonseca F, Serrano A. Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats. Dis Model Mech 2015;8:1213-25. [PMID: 26438694 DOI: 10.1242/dmm.019919] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
335 Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol Aspects Med. 2008;29:9-16. [PMID: 18045675 DOI: 10.1016/j.mam.2007.09.004] [Cited by in Crossref: 194] [Cited by in F6Publishing: 167] [Article Influence: 13.9] [Reference Citation Analysis]
336 Kaddai V, Negro F. Current understanding of insulin resistance in hepatitis C. Expert Review of Gastroenterology & Hepatology 2014;5:503-16. [DOI: 10.1586/egh.11.43] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
337 Smith BK, Marcinko K, Desjardins EM, Lally JS, Ford RJ, Steinberg GR. Treatment of nonalcoholic fatty liver disease: role of AMPK. Am J Physiol Endocrinol Metab. 2016;311:E730-E740. [PMID: 27577854 DOI: 10.1152/ajpendo.00225.2016] [Cited by in Crossref: 189] [Cited by in F6Publishing: 161] [Article Influence: 37.8] [Reference Citation Analysis]
338 Kwak M, Kim E, Jang EJ, Lee C. The association of non-alcoholic fatty liver disease with lung function: A survey design analysis using propensity score: NAFLD and lung function. Respirology 2018;23:82-8. [DOI: 10.1111/resp.13127] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
339 Sabath E, Báez-Ruiz A, Buijs RM. Non-alcoholic fatty liver disease as a consequence of autonomic imbalance and circadian desynchronization. Obes Rev. 2015; Jul 27. [Epub ahead of print]. [PMID: 26214605 DOI: 10.1111/obr.12308] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
340 Košuta I, Mrzljak A, Kolarić B, Vučić Lovrenčić M. Leptin as a Key Player in Insulin Resistance of Liver Cirrhosis? A Cross-Sectional Study in Liver Transplant Candidates. J Clin Med 2020;9:E560. [PMID: 32092909 DOI: 10.3390/jcm9020560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
341 Sahukari R, Punabaka J, Bhasha S, Ganjikunta VS, Ramudu SK, Kesireddy SR. Plant Compounds for the Treatment of Diabetes, a Metabolic Disorder: NF-κB as a Therapeutic Target. CPD 2020;26:4955-69. [DOI: 10.2174/1381612826666200730221035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
342 Nobili V, Manco M. Measurement of advanced glycation end products may change NASH management. J Gastroenterol Hepatol 2007;22:1354-5. [PMID: 17716339 DOI: 10.1111/j.1440-1746.2007.05019.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
343 Petta S, Cammà C, Di Marco V, Alessi N, Cabibi D, Caldarella R, Licata A, Massenti F, Tarantino G, Marchesini G, Craxì A. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008;103:1136-44. [PMID: 18477344 DOI: 10.1111/j.1572-0241.2008.01813.x] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 10.2] [Reference Citation Analysis]
344 Tsochatzis E, Papatheodoridis GV, Hadziyannis E, Georgiou A, Kafiri G, Tiniakos DG, Manesis EK, Archimandritis AJ. Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity. Scandinavian Journal of Gastroenterology 2009;43:1128-36. [DOI: 10.1080/00365520802085387] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
345 Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Digestive and Liver Disease 2009;41:615-25. [DOI: 10.1016/j.dld.2009.01.004] [Cited by in Crossref: 174] [Cited by in F6Publishing: 162] [Article Influence: 14.5] [Reference Citation Analysis]
346 Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, Tiwari U, Ferrel L, Pabst M, Bass NM, Merriman RB. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008;47:1916-1923. [PMID: 18433022 DOI: 10.1002/hep.22241] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 8.1] [Reference Citation Analysis]
347 Slocum SL, Skoko JJ, Wakabayashi N, Aja S, Yamamoto M, Kensler TW, Chartoumpekis DV. Keap1/Nrf2 pathway activation leads to a repressed hepatic gluconeogenic and lipogenic program in mice on a high-fat diet. Arch Biochem Biophys 2016;591:57-65. [PMID: 26701603 DOI: 10.1016/j.abb.2015.11.040] [Cited by in F6Publishing: 38] [Reference Citation Analysis]
348 Hung CH, Wang JH, Hu TH, Chen CH, Chang KC, Yen YH, Kuo YH, Tsai MC, Lu SN, Lee CM. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol 2010;16:2265-71. [PMID: 20458764 DOI: 10.3748/wjg.v16.i18.2265] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 64] [Article Influence: 6.7] [Reference Citation Analysis]
349 Shih PH, Shiue SJ, Chen CN, Cheng SW, Lin HY, Wu LW, Wu MS. Fucoidan and Fucoxanthin Attenuate Hepatic Steatosis and Inflammation of NAFLD through Modulation of Leptin/Adiponectin Axis. Mar Drugs 2021;19:148. [PMID: 33809062 DOI: 10.3390/md19030148] [Reference Citation Analysis]
350 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384. [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008] [Cited by in Crossref: 637] [Cited by in F6Publishing: 576] [Article Influence: 57.9] [Reference Citation Analysis]
351 Fishman S, Muzumdar RH, Atzmon G, Ma X, Yang X, Einstein FH, Barzilai N. Resistance to leptin action is the major determinant of hepatic triglyceride accumulation in vivo. FASEB J. 2007;21:53-60. [PMID: 17099068 DOI: 10.1096/fj.06-6557com] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.6] [Reference Citation Analysis]
352 Pais R, Moraru I, Ratziu V. Glitazones for human nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2011;4:325-34. [PMID: 21922031 DOI: 10.1177/1756283X11409793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
353 van den Berg EH, Corsetti JP, Bakker SJL, Dullaart RPF. Plasma ApoE elevations are associated with NAFLD: The PREVEND Study. PLoS One 2019;14:e0220659. [PMID: 31386691 DOI: 10.1371/journal.pone.0220659] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
354 Verrotti A, Di Marco G, la Torre R, Pelliccia P, Chiarelli F. Nonalcoholic fatty liver disease during valproate therapy. Eur J Pediatr. 2009;168:1391-1394. [PMID: 19184102 DOI: 10.1007/s00431-009-0927-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
355 Grønbaek H, Thomsen KL, Rungby J, Schmitz O, Vilstrup H. Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. Expert Rev Gastroenterol Hepatol. 2008;2:705-711. [PMID: 19072347 DOI: 10.1586/17474124.2.5.705] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
356 Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig Liver Dis. 2017;49:471-483. [PMID: 28215516 DOI: 10.1016/j.dld.2017.01.147] [Cited by in Crossref: 161] [Cited by in F6Publishing: 144] [Article Influence: 40.3] [Reference Citation Analysis]
357 Siddique A, Kowdley KV. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 2011;15:281-96, vii-x. [PMID: 21689613 DOI: 10.1016/j.cld.2011.03.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
358 Patel TP, Rawal K, Bagchi AK, Akolkar G, Bernardes N, Dias DDS, Gupta S, Singal PK. Insulin resistance: an additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes. Heart Fail Rev 2016;21:11-23. [DOI: 10.1007/s10741-015-9515-6] [Cited by in Crossref: 94] [Cited by in F6Publishing: 64] [Article Influence: 15.7] [Reference Citation Analysis]
359 van der Poorten D, George J. Current and novel therapies for the treatment of nonalcoholic steatohepatitis. Hepatol Int 2007;1:343-54. [PMID: 19669329 DOI: 10.1007/s12072-007-9011-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
360 Jeen YM, Jin SY. [Pathology of nonalcoholic steatohepatitis]. Korean J Hepatol. 2009;15:122-130. [PMID: 19581764 DOI: 10.3350/kjhep.2009.15.2.122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
361 Ferreira DM, Castro RE, Machado MV, Evangelista T, Silvestre A, Costa A, Coutinho J, Carepa F, Cortez-Pinto H, Rodrigues CM. Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease. Diabetologia. 2011;54:1788-1798. [PMID: 21455726 DOI: 10.1007/s00125-011-2130-8] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 6.2] [Reference Citation Analysis]
362 Della Torre S, Benedusi V, Fontana R, Maggi A. Energy metabolism and fertility: a balance preserved for female health. Nat Rev Endocrinol 2014;10:13-23. [PMID: 24146033 DOI: 10.1038/nrendo.2013.203] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
363 Jaruvongvanich V, Sanguankeo A, Upala S. Significant Association Between Gallstone Disease and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2016;61:2389-2396. [PMID: 26993825 DOI: 10.1007/s10620-016-4125-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 5.4] [Reference Citation Analysis]
364 Gentile S, Guarino G, Strollo F, Romano M, Genovese S, Masarone M, Ceriello A. Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus. Diabetes Res Clin Pract 2016;113:179-86. [PMID: 26803356 DOI: 10.1016/j.diabres.2015.12.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
365 Tribonias G, Margariti E, Tiniakos D, Pectasides D, Papatheodoridis GV. Liver Function Breath Tests for Differentiation of Steatohepatitis From Simple Fatty Liver in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2014;48:59-65. [DOI: 10.1097/mcg.0000000000000036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
366 Wan X, Xu C, Lin Y, Lu C, Li D, Sang J, He H, Liu X, Li Y, Yu C. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64:925-932. [PMID: 26639394 DOI: 10.1016/j.jhep.2015.11.022] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 12.3] [Reference Citation Analysis]
367 Degli Esposti D, Hamelin J, Bosselut N, Saffroy R, Sebagh M, Pommier A, Martel C, Lemoine A. Mitochondrial roles and cytoprotection in chronic liver injury. Biochem Res Int 2012;2012:387626. [PMID: 22745910 DOI: 10.1155/2012/387626] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 6.9] [Reference Citation Analysis]
368 Tseng HL, Yang SC, Yang SH, Shieh KR. Hepatic circadian-clock system altered by insulin resistance, diabetes and insulin sensitizer in mice. PLoS One 2015;10:e0120380. [PMID: 25799429 DOI: 10.1371/journal.pone.0120380] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
369 Goossens N, Negro F. The impact of obesity and metabolic syndrome on chronic hepatitis C. Clin Liver Dis. 2014;18:147-156. [PMID: 24274870 DOI: 10.1016/j.cld.2013.09.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
370 Venojärvi M, Wasenius N, Manderoos S, Heinonen OJ, Hernelahti M, Lindholm H, Surakka J, Lindström J, Aunola S, Atalay M, Eriksson JG. Nordic walking decreased circulating chemerin and leptin concentrations in middle-aged men with impaired glucose regulation. Annals of Medicine 2012;45:162-70. [DOI: 10.3109/07853890.2012.727020] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
371 Nass KJ, van den Berg EH, Faber KN, Schreuder TC, Blokzijl H, Dullaart RP. High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study. Metabolism 2017;72:37-46. [DOI: 10.1016/j.metabol.2017.04.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
372 Lim LG, Cheng CL, Wee A, Lim SG, Lee YM, Sutedja DS, Da Costa M, Prabhakaran K, Wai CT. Prevalence and clinical associations of posttransplant fatty liver disease. Liver Int. 2007;27:76-80. [PMID: 17241384 DOI: 10.1111/j.1478-3231.2006.01396.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
373 Chen L, Chen Y, Wang X, Li H, Zhang H, Gong J, Shen S, Yin W, Hu H. Efficacy and safety of oral branched-chain amino acid supplementation in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis. Nutr J. 2015;14:67. [PMID: 26155840 DOI: 10.1186/s12937-015-0056-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
374 Piro S, Spadaro L, Russello M, Spampinato D, Oliveri C, Vasquez E, Benigno R, Brancato F, Purrello F, Rabuazzo A. Molecular determinants of insulin resistance, cell apoptosis and lipid accumulation in non-alcoholic steatohepatitis. Nutrition, Metabolism and Cardiovascular Diseases 2008;18:545-52. [DOI: 10.1016/j.numecd.2007.08.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
375 Pannu N, Bhatnagar A. Resveratrol: from enhanced biosynthesis and bioavailability to multitargeting chronic diseases. Biomed Pharmacother 2019;109:2237-51. [PMID: 30551481 DOI: 10.1016/j.biopha.2018.11.075] [Cited by in Crossref: 55] [Cited by in F6Publishing: 39] [Article Influence: 18.3] [Reference Citation Analysis]
376 De Gaetano A, Gaz C, Palumbo P, Panunzi S. A Unifying Organ Model of Pancreatic Insulin Secretion. PLoS One 2015;10:e0142344. [PMID: 26555895 DOI: 10.1371/journal.pone.0142344] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
377 Boyraz M, Pirgon Ö, Dündar B, Çekmez F, Hatipoğlu N. Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease. J Clin Res Pediatr Endocrinol 2015;7:121-7. [PMID: 26316434 DOI: 10.4274/jcrpe.1749] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 8.4] [Reference Citation Analysis]
378 Armandi A, Schattenberg JM. Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches. Nutrients 2021;13:1977. [PMID: 34201382 DOI: 10.3390/nu13061977] [Reference Citation Analysis]
379 Macaluso FS, Maida M, Minissale MG, Li Vigni T, Attardo S, Orlando E, Petta S. Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int. 2013;2013:564645. [PMID: 23956991 DOI: 10.1155/2013/564645] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
380 Shirakawa K, Endo J, Katsumata Y, Yamamoto T, Kataoka M, Isobe S, Yoshida N, Fukuda K, Sano M. Negative legacy of obesity. PLoS One 2017;12:e0186303. [PMID: 29073165 DOI: 10.1371/journal.pone.0186303] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
381 Loria P, Adinolfi L, Bellentani S, Bugianesi E, Grieco A, Fargion S, Gasbarrini A, Loguercio C, Lonardo A, Marchesini G, Marra F, Persico M, Prati D, Baroni GS. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. Digestive and Liver Disease 2010;42:272-82. [DOI: 10.1016/j.dld.2010.01.021] [Cited by in Crossref: 150] [Cited by in F6Publishing: 140] [Article Influence: 13.6] [Reference Citation Analysis]
382 van den Berg EH, Flores-Guerrero JL, Gruppen EG, de Borst MH, Wolak-Dinsmore J, Connelly MA, Bakker SJL, Dullaart RPF. Non-Alcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: Role of Circulating Branched-Chain Amino Acids. Nutrients 2019;11:E705. [PMID: 30917546 DOI: 10.3390/nu11030705] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
383 Doycheva I, Loomba R. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). Adv Ther. 2014;31:30-43. [PMID: 24385405 DOI: 10.1007/s12325-013-0084-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
384 Zhao R, Xiang B, Dolinsky VW, Xia M, Shen GX. Saskatoon berry powder reduces hepatic steatosis and insulin resistance in high fat-high sucrose diet-induced obese mice. J Nutr Biochem 2021;95:108778. [PMID: 34004342 DOI: 10.1016/j.jnutbio.2021.108778] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
385 Taher J, Baker C, Alvares D, Ijaz L, Hussain M, Adeli K. GLP-2 Dysregulates Hepatic Lipoprotein Metabolism, Inducing Fatty Liver and VLDL Overproduction in Male Hamsters and Mice. Endocrinology 2018;159:3340-50. [DOI: 10.1210/en.2018-00416] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
386 Tahara A, Takasu T. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model. Physiol Rep 2019;7:e14286. [PMID: 31782258 DOI: 10.14814/phy2.14286] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
387 Liu CQ, He CM, Chen N, Wang D, Shi X, Liu Y, Zeng X, Yan B, Liu S, Yang S, Li X, Li X, Li Z. Serum uric acid is independently and linearly associated with risk of nonalcoholic fatty liver disease in obese Chinese adults. Sci Rep. 2016;6:38605. [PMID: 27924915 DOI: 10.1038/srep38605] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
388 Benini F, Pigozzi MG, Pozzi A, Bercich L, Reggiani A, Quattrocchi D, Distefano L, Donati P, Cesana BM, Lanzini A. Elevation of serum gamma-glutamyltranspeptidase activity is frequent in chronic hepatitis C, and is associated with insulin resistance. Dig Liver Dis. 2009;41:586-590. [PMID: 19131283 DOI: 10.1016/j.dld.2008.11.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
389 Mendes-Braz M, Martins JO. Diabetes Mellitus and Liver Surgery: The Effect of Diabetes on Oxidative Stress and Inflammation. Mediators Inflamm 2018;2018:2456579. [PMID: 29853784 DOI: 10.1155/2018/2456579] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
390 Aller de la Fuente R, Mora Cuadrado N, Tafur C, López Gómez JJ, Gómez de la Cuesta S, García Sánchez MC, Antolin Melero B, de Luis Román DA. Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes. Endocrinología, Diabetes y Nutrición 2018;65:354-60. [DOI: 10.1016/j.endinu.2017.12.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
391 Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, Sourianarayanane A, Khiyami A, Yerian L, Pai RK, Dasarathy S, McCullough AJ. Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clin. 2015;3:141-145. [PMID: 26675585 DOI: 10.1016/j.bbacli.2014.09.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
392 Zhu R, Baker SS, Moylan CA, Abdelmalek MF, Guy CD, Zamboni F, Wu D, Lin W, Liu W, Baker RD, Govindarajan S, Cao Z, Farci P, Diehl AM, Zhu L. Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers: Elevated alcohol-metabolizing genes in NAFLD. J Pathol 2016;238:531-42. [DOI: 10.1002/path.4650] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
393 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
394 Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, Bastard JP, Poupon R, Housset C, Capeau J. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int. 2009;29:1431-1438. [PMID: 19422483 DOI: 10.1111/j.1478-3231.2009.02022.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 7.8] [Reference Citation Analysis]
395 Song YA, Kwon S, Doo SW, Kim JH, Yang WJ, Song YS. Is There Any Relation Between the Degree of Fatty Liver Disease and Severity of Lower Urinary Tract Symptoms? Urology 2016;89:90-5. [DOI: 10.1016/j.urology.2015.11.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
396 Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: does it matter? J Hepatol. 2012;56 Suppl 1:S56-S65. [PMID: 22300466 DOI: 10.1016/s0168-8278(12)60007-5] [Cited by in Crossref: 124] [Cited by in F6Publishing: 43] [Article Influence: 13.8] [Reference Citation Analysis]
397 Huang RC, Mori TA, Burke V, Newnham J, Stanley FJ, Landau LI, Kendall GE, Oddy WH, Beilin LJ. Synergy between adiposity, insulin resistance, metabolic risk factors, and inflammation in adolescents. Diabetes Care 2009;32:695-701. [PMID: 19131468 DOI: 10.2337/dc08-1917] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 5.5] [Reference Citation Analysis]
398 Sanna C, Rosso C, Marietti M, Bugianesi E. Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. Int J Mol Sci. 2016;17:pii: E717. [PMID: 27187365 DOI: 10.3390/ijms17050717] [Cited by in Crossref: 93] [Cited by in F6Publishing: 81] [Article Influence: 18.6] [Reference Citation Analysis]
399 Okamura T, Hashimoto Y, Hamaguchi M, Obora A, Kojima T, Fukui M. The visceral adiposity index is a predictor of incident nonalcoholic fatty liver disease: A population-based longitudinal study. Clinics and Research in Hepatology and Gastroenterology 2020;44:375-83. [DOI: 10.1016/j.clinre.2019.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
400 Lonardo A, Carani C, Carulli N, Loria P. ‘Endocrine NAFLD’ a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol. 2006;44:1196-1207. [PMID: 16618516 DOI: 10.1016/j.jhep.2006.03.005] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 5.5] [Reference Citation Analysis]
401 Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, Douhara A, Yamao J, Fujimoto M, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Uejima M, Uemura M, Fukui H. Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance. Oncol Rep 2013;30:545-52. [PMID: 23708326 DOI: 10.3892/or.2013.2497] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
402 Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzioni M, De Minicis S, Nobili L, Salzano R, Omenetti A, Pacetti D, Sigmund S, Benedetti A, Casini A. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006;169:846-60. [PMID: 16936261 DOI: 10.2353/ajpath.2006.050953] [Cited by in Crossref: 191] [Cited by in F6Publishing: 178] [Article Influence: 12.7] [Reference Citation Analysis]
403 Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Oza N, Nakashita S, Hara M, Iwane S, Takahashi H, Akiyama T. Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation. Liver Int. 2009;29:213-220. [PMID: 18710430 DOI: 10.1111/j.1478-3231.2008.01853.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
404 Silva P, Fernandes E, Carvalho F. Dual effect of red wine on liver redox status: a concise and mechanistic review. Arch Toxicol 2015;89:1681-93. [DOI: 10.1007/s00204-015-1538-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
405 Gorginzadeh M, Safari S, Alavian SM. Acute Fatty Liver of Pregnancy: A Life-Threatening Condition Requiring a Life-Saving Approach. Hepat Mon 2016;16:e35256. [PMID: 27630721 DOI: 10.5812/hepatmon.35256] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
406 Francque S, Laleman W, Verbeke L, Van Steenkiste C, Casteleyn C, Kwanten W, Van Dyck C, D'hondt M, Ramon A, Vermeulen W, De Winter B, Van Marck E, Van Marck V, Pelckmans P, Michielsen P. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Invest 2012;92:1428-39. [DOI: 10.1038/labinvest.2012.103] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 7.0] [Reference Citation Analysis]
407 Tanaka K, Tsuji I, Tamakoshi A, Matsuo K, Ito H, Wakai K, Nagata C, Mizoue T, Sasazuki S, Inoue M, Tsugane S, Tsugane S, Inoue M, Sasazuki S, Iwasaki M, Otani T, Sawada N, Shimazu T, Tsuji I, Tsubono Y, Nishino Y, Tamakoshi A, Matsuo K, Ito H, Wakai K, Nagata C, Mizoue T, Tanaka K; for the Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan. Obesity and Liver Cancer Risk: An Evaluation Based on a Systematic Review of Epidemiologic Evidence Among the Japanese Population. Japanese Journal of Clinical Oncology 2012;42:212-21. [DOI: 10.1093/jjco/hyr198] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
408 Mahale AR, Prabhu SD, Nachiappan M, Fernandes M, Ullal S. Clinical relevance of reporting fatty liver on ultrasound in asymptomatic patients during routine health checkups. J Int Med Res 2018;46:4447-54. [PMID: 30185098 DOI: 10.1177/0300060518793039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
409 de Castro MRT, Ferreira APO, Busanello GL, da Silva LRH, da Silveira Junior MEP, Fiorin FDS, Arrifano G, Crespo-López ME, Barcelos RP, Cuevas MJ, Bresciani G, González-Gallego J, Fighera MR, Royes LFF. Previous physical exercise alters the hepatic profile of oxidative-inflammatory status and limits the secondary brain damage induced by severe traumatic brain injury in rats. J Physiol 2017;595:6023-44. [PMID: 28726269 DOI: 10.1113/JP273933] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
410 Yao J, Zhi M, Minhu C. Effect of silybin on high-fat-induced fatty liver in rats. Braz J Med Biol Res 2011;44:652-9. [DOI: 10.1590/s0100-879x2011007500083] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
411 Li X, Wang Z, Klaunig JE. The effects of perfluorooctanoate on high fat diet induced non-alcoholic fatty liver disease in mice. Toxicology 2019;416:1-14. [DOI: 10.1016/j.tox.2019.01.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
412 Parvaiz F, Manzoor S, Tariq H, Javed F, Fatima K, Qadri I. Hepatitis C virus infection: molecular pathways to insulin resistance. Virol J. 2011;8:474. [PMID: 22008087 DOI: 10.1186/1743-422x-8-474] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
413 Tsochatzis E, Manolakopoulos S, Papatheodoridis GV, Hadziyannis E, Triantos C, Zisimopoulos K, Goulis I, Tzourmakliotis D, Akriviadis E, Manesis EK. Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study. Aliment Pharmacol Ther. 2009;30:947-954. [PMID: 19604179 DOI: 10.1111/j.1365-2036.2009.04094.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
414 M. Brunt E, G. Tiniakos D. Fatty Liver Disease. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Elsevier; 2009. pp. 1087-114. [DOI: 10.1016/b978-141604059-0.50044-8] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
415 Zhao S, Wang Y, Wu W, Yang S, Feng L, Tao F, Ge W, Shen M, Xu W. Nonalcoholic fatty liver disease and risk of prostatic diseases: Roles of insulin resistance. Andrologia 2021;53:e14060. [PMID: 33782980 DOI: 10.1111/and.14060] [Reference Citation Analysis]
416 Ricci G, Canducci E, Pasini V, Rossi A, Bersani G, Ricci E, Alvisi V. Nutrient intake in Italian obese patients: Relationships with insulin resistance and markers of non-alcoholic fatty liver disease. Nutrition 2011;27:672-6. [DOI: 10.1016/j.nut.2010.07.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
417 Rezazadeh H, Sharifi MR, Sharifi M, Soltani N. Gamma-aminobutyric acid attenuates insulin resistance in type 2 diabetic patients and reduces the risk of insulin resistance in their offspring. Biomed Pharmacother 2021;138:111440. [PMID: 33667789 DOI: 10.1016/j.biopha.2021.111440] [Reference Citation Analysis]
418 Malnick S, Maor Y. The Interplay between Alcoholic Liver Disease, Obesity, and the Metabolic Syndrome. Visc Med 2020;36:198-205. [PMID: 32775350 DOI: 10.1159/000507233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
419 Moucari R, Asselah T, Cazals–hatem D, Voitot H, Boyer N, Ripault M, Sobesky R, Martinot–peignoux M, Maylin S, Nicolas–chanoine M, Paradis V, Vidaud M, Valla D, Bedossa P, Marcellin P. Insulin Resistance in Chronic Hepatitis C: Association With Genotypes 1 and 4, Serum HCV RNA Level, and Liver Fibrosis. Gastroenterology 2008;134:416-23. [DOI: 10.1053/j.gastro.2007.11.010] [Cited by in Crossref: 352] [Cited by in F6Publishing: 313] [Article Influence: 27.1] [Reference Citation Analysis]
420 de Assis AM, Rech A, Longoni A, Rotta LN, Denardin CC, Pasquali MA, Souza DO, Perry ML, Moreira JC. Ω3-Polyunsaturated fatty acids prevent lipoperoxidation, modulate antioxidant enzymes, and reduce lipid content but do not alter glycogen metabolism in the livers of diabetic rats fed on a high fat thermolyzed diet. Mol Cell Biochem 2012;361:151-60. [PMID: 21989716 DOI: 10.1007/s11010-011-1099-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
421 Cammà C, Petta S. Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future. Journal of Hepatology 2009;50:648-51. [DOI: 10.1016/j.jhep.2009.01.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
422 Cobbold JFL, Anstee QM, Taylor-robinson SD. The importance of fatty liver disease in clinical practice. Proc Nutr Soc 2010;69:518-27. [DOI: 10.1017/s0029665110001916] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
423 Bruno Ade S, Rodrigues MH, Alvares MC, Nahas-Neto J, Nahas EA. Non-alcoholic fatty liver disease and its associated risk factors in Brazilian postmenopausal women. Climacteric. 2014;17:465-471. [PMID: 24517420 DOI: 10.3109/13697137.2014.881353] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
424 Parks BW, Sallam T, Mehrabian M, Psychogios N, Hui ST, Norheim F, Castellani LW, Rau CD, Pan C, Phun J, Zhou Z, Yang WP, Neuhaus I, Gargalovic PS, Kirchgessner TG, Graham M, Lee R, Tontonoz P, Gerszten RE, Hevener AL, Lusis AJ. Genetic architecture of insulin resistance in the mouse. Cell Metab 2015;21:334-47. [PMID: 25651185 DOI: 10.1016/j.cmet.2015.01.002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 95] [Article Influence: 22.6] [Reference Citation Analysis]
425 Oh S, Cho Y, Kang M, Yoo T, Park J, Kim H, Park D, Sohn C, Jeon W, Kim B, Son B, Shin J. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 2006;55:1604-9. [DOI: 10.1016/j.metabol.2006.07.021] [Cited by in Crossref: 79] [Cited by in F6Publishing: 64] [Article Influence: 5.3] [Reference Citation Analysis]
426 Hung CH, Lee CM, Lu SN. Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. Expert Rev Anti Infect Ther 2011;9:525-33. [PMID: 21609264 DOI: 10.1586/eri.11.33] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
427 Chai SY, Pan XY, Song KX, Huang YY, Li F, Cheng XY, Qu S. Differential patterns of insulin secretion and sensitivity in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease versus patients with type 2 diabetes mellitus alone. Lipids Health Dis 2014;13:7. [PMID: 24397589 DOI: 10.1186/1476-511X-13-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
428 Campana B, Calabrese D, Matter MS, Terracciano LM, Wieland SF, Heim MH. In vivo analysis at the cellular level reveals similar steatosis induction in both hepatitis C virus genotype 1 and 3 infections. J Viral Hepat 2018;25:262-71. [PMID: 29086446 DOI: 10.1111/jvh.12816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
429 Nass KJ, van den Berg EH, Gruppen EG, Dullaart RPF. Plasma lecithin:cholesterol acyltransferase and phospholipid transfer protein activity independently associate with nonalcoholic fatty liver disease. Eur J Clin Invest. 2018;48:e12988. [PMID: 29947103 DOI: 10.1111/eci.12988] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
430 Schofield Z, Reed MA, Newsome PN, Adams DH, Günther UL, Lalor PF. Changes in human hepatic metabolism in steatosis and cirrhosis. World J Gastroenterol 2017;23:2685-95. [PMID: 28487605 DOI: 10.3748/wjg.v23.i15.2685] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
431 Zhang L, Xu J, Song H, Yao Z, Ji G. Extracts from Salvia-Nelumbinis naturalis alleviate hepatosteatosis via improving hepatic insulin sensitivity. J Transl Med 2014;12:236. [PMID: 25160038 DOI: 10.1186/s12967-014-0236-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
432 Li H, Meng Q, Xiao F, Chen S, Du Y, Yu J, Wang C, Guo F. ATF4 deficiency protects mice from high-carbohydrate-diet-induced liver steatosis. Biochem J 2011;438:283-9. [PMID: 21644928 DOI: 10.1042/BJ20110263] [Cited by in Crossref: 43] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]